

A Systematic Review and Meta-Analysis of Digital Application use in **Clinical Research in Pain Medicine**

- Ashish Shetty^{2**}, Gayathri Delanerolle^{1**}, Yutian Zeng^{8,9***}, Jian Qing Shi^{8,9}****, Rawan 1
- Ebrahim³, Joanna Pang⁴, Dharani Hapangama⁶, Martin Sillem¹³, Suchith Shetty¹⁸ 2
- 3
- Balakrishnan Shetty¹⁵, Martin Hirsch^{10,3}, Vanessa Raymont¹⁷, Kingshuk Majumder⁷, Sam Chong^{2,3}, William Goodison², Rebecca O'Hara¹¹, Louise Hull¹¹, Nicola Pluchino¹², Naresh Shetty¹⁴, Sohier Elneil^{2,3}***, Tacson Fernandez^{3,16}, *Peter Phiri^{4,5}***, Robert Brownstone^{2,3}*** 4
- 5
- 6
- ¹University of Oxford, Oxford, UK 7
- ²University College London Hospitals NHS Foundation Trust, London, UK 8
- ³University College London, London, UK 9
- ⁴Southern Health NHS Foundation Trust, Southampton, UK 10
- ⁵University of Southampton, Primary Care, Population Sciences and Medical Education Division, 11
- 12 Southampton, UK
- ⁶Liverpool Women's NHS Foundation, Liverpool, UK 13
- ⁷University of Manchester NHS Foundation Trust, Manchester, UK 14
- ⁸Southern University of Science and Technology, Shenzhen, China 15
- ⁹Alan Turing Institute, London, UK 16
- ¹⁰Oxford University Hospitals NHS Foundation Trust, Oxford, UK 17
- ¹¹Robinson Research Institute, University of Adelaide, Adelaide, Australia 18
- 19 ¹²University of Geneva, Geneva, Switzerland
- ¹³Praxisklinik am Rosengarten Mannheim, Saarland University Medical Centre, Homburg, Germany 20
- ¹⁴M.S. Ramaiah Medical College, Bangalore, India 21
- ¹⁵Sri Siddhartha University, Tumkur, India 22
- ¹⁶Royal National Orthopaedic Hospital, London, UK 23
- ¹⁷Department of Psychiatry, University of Oxford, Oxford, UK 24
- 25 ¹⁸Eötvös Loránd University, Budapest, Hungary
- **These authors share first authorship 26
- 27 ***These authors share second authorship
- ****These authors share last authorship 28

29 * Correspondence:

- Dr Peter Phiri 30
- Peter.Phiri@southernhealth.nhs.uk 31
- 32 This submission is formatted in British English.
- 33
- 34 Keywords: chronic pain, pain management, digital app, digital medicine, mHealth
- 35
- 36

37 Abstract

- 38 Importance
- 39 Pain is a silent global epidemic impacting approximately a third of the population. Pharmacological
- 40 and surgical interventions are primary modes of treatment. Cognitive/behavioural management
- 41 approaches and interventional pain management strategies are approaches that have been used to
- 42 assist with the management of chronic pain. Accurate data collection and reporting treatment
- 43 outcomes are vital to addressing the challenges faced. In light of this, we conducted a systematic
- 44 evaluation of the current digital application landscape within chronic pain medicine.

45 *Objective*

- 46 The primary objective was to consider the prevalence of digital application usage for chronic pain
- 47 management. These digital applications included mobile apps, web apps, and chatbots.

48 Data Sources

- 49 We conducted searches on PubMed and ScienceDirect for studies that were published between 1st
- 50 January 1990 and 1st January 2021.

51 Study Selection

- 52 Our review included studies that involved the use of digital applications for chronic pain conditions.
- 53 There were no restrictions on the country in which the study was conducted. Only studies that were
- 54 peer-reviewed and published in English were included. Four reviewers had assessed the eligibility of
- each study against the inclusion/exclusion criteria. Out of the 84 studies that were initially identified,
- 56 38 were included in the systematic review.
- 57 Data Extraction and Synthesis
- 58 The AMSTAR guidelines were used to assess data quality. This assessment was carried out by 3
- 59 reviewers. The data were pooled using a random-effects model.
- 60 *Main Outcome(s) and Measure(s)*
- 61 Before data collection began, the primary outcome was to report on the prevalence of digital
- 62 application usage for chronic pain conditions. We also recorded the type of digital application studied
- 63 (e.g. mobile application, web application) and, where the data was available, the prevalence of pain
- 64 intensity, pain inferences, depression, anxiety, and fatigue.
- 65 Results
- 66 38 studies were included in the systematic review and 22 studies were included in the meta-analysis.
- 67 The digital interventions were categorised to web and mobile applications and chatbots, with pooled
- 68 prevalence of 0.22 (95% CI -0.16, 0.60), 0.30 (95% CI 0.00, 0.60) and -0.02 (95% CI -0.47, 0.42)
- 69 respectively. Pooled standard mean differences for symptomatologies of pain intensity, depression,
- 70 and anxiety symptoms were 0.25 (95% CI 0.03, 0.46), 0.30 (95% CI 0.17, 0.43) and 0.37 (95% CI
- 71 0.05, 0.69) respectively.
- A sub-group analysis was conducted on pain intensity due to the heterogeneity of the results
- 73 $(I^2=82.86\%; p=0.02)$. After stratifying by country, we found that digital applications were more
- 74 likely to be effective in some countries (e.g. USA, China) than others (e.g. Ireland, Norway).

75

Running Title

76 Conclusions and Relevance

- The use of digital applications in improving pain-related symptoms shows promise, but further 77
- clinical studies would be needed to develop more robust applications. 78
- 79

80 Introduction

- 81 High-quality research data generated by scientifically robust study designs, improved use of clinical
- 82 data, and the development of cost-effective healthcare models can change how medicine is practiced
- 83 in the modern world. Digital medicine (DM), wherein multimodal and multidimensional digital tools
- 84 are used to intervene in accessing and providing healthcare, is now a fundamental part of these
- 85 drivers of change.
- 86 Despite relative growth profoundly impacting gross economic improvement, 'bench to bedside'
- 87 pathways still take considerable time (). Equally robust research evaluations have not kept pace with
- 88 a growing global population, although, the intellectual and healthcare evolution has modernised
- 89 clinical practice by way of clinical research. Existing clinical evidence and incorporation of
- 90 information technology has led to more prominent use of DM. A fundamental aspect of DM is to
- 91 improve and promote evidence-based medicine (EBM) and/or evidence-based practices (EBP) within
- 92 clinical and healthcare frameworks, underpinned by data science and technologies.
- 93 The field of pain medicine in adults is a particularly challenging area of clinical practice for many
- 94 reasons, including subjectivity associated with patient-reported outcomes and management of
- 95 symptomatology with limited information on pathophysiology (). Considering this uncertainty,
- 96 attempts by clinicians to categorise pain and decide on treatment interventions (Supplementary Table
- 97 1), could benefit from the concepts of DM and its associates of EBM and EBP. Pain is often the
- 98 commonest symptom that patients present with in outpatient clinics. The need for individualised care
- 99 based on generalisable research is complicated by wide variables, subjective nature, and inherent bias
- 100 which provide a unique set of challenges for a simple protocol to work. The use of cognitive
- 101 technology such as artificial intelligence, in delivering personalised care, based on available
- 102 evidence, is therefore an attractive proposition for pain medicine.
- 103 [SUPPLEMENTARY TABLE 1]

104 Pain medicine has been identified as a specialty that would vastly benefit from the personalisation of 105 care.¹ A current example of this need is the variable efficacy of pharmacotherapy in relieving chronic 106 pain. Opioids, for instance, have been routinely used to treat chronic pain syndromes, despite only modest evidence for their use.² This has the potential for significant harm in patients where it has 107 108 been used inappropriately and may have influenced factors that led to the Opioid Crisis globally, 109 especially so in the USA and UK. Traditional pain evaluation methods are vulnerable to recall error and bias as they rely on retrospective reporting of pain variations.³ Pain perception combined with 110 measuring functional changes and physiological parameters affected by pain are important secondary 111 112 outcome data to assess efficacy. Methods demanding frequent, repeated pain evaluation and painassociated features are required to formulate chronic pain management strategies.^{4,5} This approach 113 114 was previously hindered both by the resources required for such vast data collection, and the 115 complexity of the statistical analysis required to interpret the resulting datasets.⁶

- 117 To advance DM concepts and their use in pain medicine research, it is imperative to assess the global
- regulatory sphere. Over the last decade, a plethora of legislations and regulatory guidelines around 118
- 119 DM have been developed by the World Health Organisation (WHO),⁷ Medicines and Healthcare
- products Regulatory Agency (MHRA),⁸ Food and Drug Administration (FDA)⁹ and National 120 Institute for Health and Care Excellence (NICE)¹⁰ (Supplementary Table 2). However, there are
- 121 122 complexities around evaluating Artificial Intelligence (AI)-based applications that fall under the
- 123 category of DM. This includes those using algorithms based on machine learning (ML) models that
- 124 may be categorised as a medical device. Furthermore, development of AI applications requires
- 125 documentary evidence that the planning, designing, and development phases meet the globally
- 126 accepted Internationally Organisation for Standardisation (ISO) standards. In order to achieve ISO
- 127 standards, a high proficiency of conformances should be maintained by the research group
- 128 responsible for developing the intervention that could be mass produced. As part of this
- 129 standardisation process, the intervention may undergo several non-conformity assessments as well as
- 130 vigorous testing and validation prior to being deployed.

131 [SUPPLEMENTARY TABLE 2]

- The regulatory and standards required for novel innovations are also dependent on the disease 132
- 133 classification. The current classification of chronic and acute pain conditions (Figure 1 and Figure 2
- 134 respectively) employs the guidelines published by the International Association for the Study of Pain.
- 135 Clinicians evaluating both chronic and acute chronic pain are considering changes to guidelines to
- provide better diagnoses and improve outcomes for patients. Advancements in the understanding of 136
- 137 the pathophysiology of acute and chronic pain have resulted in effective pharmacological approaches
- 138 to sub-populations of patients.
- 139 [FIGURE 1]
- 140 [FIGURE 2]

141 A critical step of DM is the development of digital tools using large sets of datasets and aggregated

142 data to create novel paradigms of care. This is also referred to as evidence-based digital medicine

- 143 which uses EBM concepts. To disperse these paradigms, computer programming, utility and broad
- 144 access of applications are vital. The development of smartphone applications is key to deliver the
- 145 DM phenomenon to facilitate communication and engagement between clinicians and patients. A key
- 146 element would be to personalise both treatments and applications using sensors and programming
- 147 capabilities that would support significant benefits as summarised in Supplementary Table 3.

148 [SUPPLEMENTARY TABLE 3]

- 149 Evaluating the current DM landscape is equally important as developing novel applications. The
- 150 accessibility of smartphones has given rise to multiple pilots of app-based longitudinal assessment
- programmes for chronic pain, which have shown promising early results.^{11,12} Furthermore, the use of 151
- 152 validated lifestyle devices such as the FitBit® as monitoring adjuncts could be combined with
- 153 questionnaires and activity programmes to allow regular functional reassessment among chronic pain
- patients.¹³ 154
- Therefore, the primary aims of this study were to: (1) identify and report the current prevalence of 155
- 156 DM application in pain medicine; (2) identify and report the current DM application use within pain
- 157 medicine. To achieve this, we aimed to explore the prevalence of these types of assessments' use and
- 158 deployment of these using DM applications.

Running Title

159 Materials and methods

- 160 An evidence synthesis methodology was developed for the purpose of this study, with a systematic
- 161 review protocol published on PROSPERO (CRD42021248232). The Preferred Reporting Items for
- Systematic Reviews and Meta-analyses (PRISMA) was used to report findings. 162

163 Search strategy and study selection

- 164 PubMed and ScienceDirect were used to identify relevant studies that were peer-reviewed and
- 165 published in English between the 1st of January 1990 and 1st of January 2021. Search terms used
- 166 included Chronic Pain, Pain Clinical Trials, Pain medicine, Pain medicine clinical research and
- 167 Digital Clinical Trials. All studies using DM applications for chronic pain conditions were included.
- 168 Only studies that were peer-reviewed and published in English were included. Suitable publications
- 169 were selected using the PICO (Population/Participants, Intervention(s), Comparison, Outcome)
- 170 strategy. An independent reviewer screened studies included within the study by reading the full text.
- 171 Initial title and abstracts for identified articles were screened by 4 investigators. Inclusion and
- 172 exclusion criteria were assessed against each study. This was followed with the screening of the full
- 173 study article independently by 2 investigators and included into the final data pool.
- 174 Data extraction and synthesis
- 175 The data extraction process involved reading titles and abstracts followed by the application of the
- 176 refinement protocol where the full text was reviewed and subsequently verified. Key study details
- 177 such as study title, citation details, methods, findings, limitations, characteristics of the study and
- 178 conclusions were extracted. Differing opinions were resolved by review and discussion between the
- 179 lead authors. The authors remained unblinded regarding the publisher details. A full methodological
- 180 description is demonstrated within the supplementary document (Figure 3).
- 181 [FIGURE 3]
- 182 Data analysis
- 183 As all studies reported the mean and SD at several time points, a mathematical model was formulated 184 as demonstrated in Supplementary Figure 1.
- 185 [SUPPLEMENTARY FIGURE 1]
- 186 BPI, NRS, PCP-S and pain evaluation questionnaires were used to assess pain intensity and pain
- 187 interference: HADS, CES-D, BDI, PHO-9, DASS, GAD-7 and STAI were used to assess depression
- 188 and anxiety; FSS and MOS sleep scale were used to assess fatigue and sleep. All studies reported the
- 189 mean and SD of the questionnaires across several timepoints, at baseline and follow-up. The baseline
- questionnaire score was subtracted from the follow-up questionnaire score to standardize the data and 190
- 191 remove the initial effect. Score changes between these two time points reflect the treatment effect.
- $(x_e^0 x_e^1)$ represented the change in the questionnaire scores between baseline (⁰) and follow-up (¹) in the treatment group, which also indicated an improvement of treatments, and $(x_c^0 x_c^1)$ represented the change in the questionnaire scores between baseline (⁰) and follow-up (¹) in the 192
- 193
- 194
- 195 control group.
- Therefore, $(x_e^0 x_e^1) (x_c^0 x_c^1)$ showed the mean difference (MD) of the change of score between the two groups, which is the outcome of focus. If $(x_e^0 x_e^1) (x_c^0 x_c^1)$ is positive, it indicates the treatment was beneficial for patients in improving symptoms of pain. However, if $(x_e^0 x_e^1) (x_e^0 x_e^0) (x_e^0$ 196
- 197
- 198
- $(x_c^0 x_c^1)$ is negative, it indicates the treatment had no effect on improving pain. 199

200
$$MD = (x_{\varepsilon}^{0} - x_{\varepsilon}^{1}) - (x_{\varepsilon}^{0} - x_{\varepsilon}^{1})$$

$$MD \sim \mathcal{N}((m_e^0 - m_e^1) - (m_e^0 - m_e^1)), \frac{s_e^{0^2}}{n_e^0} + \frac{s_e^{1^2}}{n_e^1} + \frac{s_e^{0^2}}{n_e^0} + \frac{s_e^{1^2}}{n_e^1})$$

201

202 The scales of the questionnaires were different, therefore standardized mean differences (SMD) were

203 used to illustrate the change in the mean score of the treatment group versus the control group from

204 baseline to follow-up. The traditional form of SMD was

$$\widehat{g_k} = (1 - \frac{3}{4n_k - 9}) \frac{\widehat{u_{ek}} - \widehat{u_{ck}}}{\sqrt{((n_{ek} - 1)s_{ek}^2 + (n_{ck} - 1)s_{ck}^2)/(n_k - 2)}}$$

$$Var(\widehat{g}_k) = \frac{n_k}{n_{ek} \cdot n_{ok}} + \frac{\widehat{g}_k^2}{2(n_k - 3.94)}$$

205

where $n_k = n_{ek} + n_{ck}$, n_{ek} , $\hat{u_{ek}}$, s_{ek} are the number, mean and standard variation of treatment group. n_{ck} , $\hat{u_{ck}}$, s_{ck} are the number, mean and standard variation of the control group. The 95% confidence interval (CI) was obtained by

209 $\widehat{g}_{k} + 1.96 * S.E.(\widehat{g}_{k})$

210 where
$$S.E.(\widehat{g_k}) = \sqrt{Var(\widehat{g_k})}$$
.

211 $\widehat{g_k}$ was transformed according to the traditional form, and $\widehat{g_k}$ and $S.E.(\widehat{g_k})$ were calculated for each

study, with a random effect model used to pool the estimators. Funnel plot graphs demonstrated the publication bias. Subgroup analysis and I^2 were used to explain heterogeneity and Egger's test was

- used to detect publication bias. All procedures were finished with STATA 16.1.
- 215 Risk of bias
- 216 The risk of bias (RoB) table (below) has been used to demonstrate the risk of bias within the

217 randomised controlled trials used in the systematic review and meta-analysis. The RoB is reflective

218 of a fixed set of biases within domains of study design, conduct and reporting. This combined with

the quality check allows the findings of the study to be scientifically justified, and clinically viable.

220 [TABLE 3]

AMSTAR was used also to assess methodological quality, where the total scores range from 0-11

- (see Figure 4, below). An article would be considered as good quality with a score of 8-11, moderate
 4-7 and low 0-3.
- 224 [FIGURE 4]
- 225 *Outcomes*

226 Outcomes of this study were reported via the meta-analysis which was based on the availability of

statistics reported by the systematically included studies. The following are the outcomes of this study:

Running Title

- 229 Prevalence of DM applications, including categories
- Prevalence of chronic pain conditions using DM applications for self-reporting purposes 230
- Prevalence of pain outcomes of depression, anxiety, pain inferences, and fatigue and sleep 231 _ 232 problems
- Clinical significance of the prevalence data 233 _
- Research significance of the prevalence data 234 -
- 235 Critical interpretation of the identified data
- 236 Common themes identified within the prevalence data -
- 237
- 238 **Results**
- The search yielded 84 publications, with $38^{11,16-52}$ included as part of the systematic review (Table 1). 239
- 240 Of the 38 studies, 7 were cross-sectional and lacked a control group. Eight studies comprised of a
- 241 control and treatment group, although they either lacked statistical information completely or
- inconsistencies were identified that were associated with the mean and SD at baseline and beta coefficients at follow-up timepoints. Therefore, $16^{25,28,29,31,33,35-40,43,46,50-52}$ were excluded and $22^{11,16-24,26,27,30,32,34,41,42,44,45,47-49}$ were included into the final meta-analysis (Table 2). 242
- 243
- 244
- 245 [TABLE 1]
- 246 [TABLE 2]
- 247 Meta-analysis
- 248 All 22 studies included in the meta-analysis reported more than one pain-related symptom. One
- 249 primary outcome reported in 15 studies was pain intensity. 11 reported depressive symptoms and 9
- 250 anxiety symptoms. Pain interference was reported by 4 studies. Fatigue and sleep problems were
- 251 included as secondary outcomes in two and one study respectively. Meta-analyses were conducted
- 252 for each outcome separately.
- 253 [FIGURE 5a]
- 254 Pain intensity

255 All 15 studies provided the mean and SD. Therefore, the meta-analysis was based on the mean and 256 SD. Figure 6 demonstrates a pooled SMD of 0.25 with a 95% CI of 0.03-0.46. SMD is statistically 257 higher than 0; therefore, pain scores within the treatment group reduced compared to the control 258 group, suggesting DM applications can significantly reduce symptoms of pain. A high heterogeneity 259 of $I^2 = 82.86\%$ was identified for this group (p=0.02). A subgroup analysis was conducted to analyse 260 the possible source of heterogeneity.

- 261 [FIGURE 5b]
- 262 **Depression**
- 263 The 11 studies reporting depressive symptoms used various assessment tools, including the Centre
- 264 for Epidemiological Studies-Depression (CES-D), Beck Depression Inventory (BDI), Patient Health
- Questionnaire-8 and -9 (PHQ-8, PHQ-9), Hospital Anxiety and Depression Scale (HADS) and the 265
- Depression Anxiety Stress Scales (DASS). Ruehlman and colleagues (2012) used CES-D and DASS 266

- **Running Title**
- 267 to assess the depression of the participants twice. To avoid duplication we used only one (CES-D) of
- 268 the means and SD of these two assessments so that 11 studies were included in meta-analysis. Figure
- 7 showed that the pooled SMD was 0.30 with a 95%CI of 0.17-0.43, suggesting the use of DM 269
- 270 applications reduced depression symptoms compared with the usual standard care, with an elevated
- heterogeneity of $I^2 = 34.72\%$ (*p*=0.00). 271
- 272 [FIGURE 5c]
- 273 Anxiety

274 Within the 9 studies reporting anxiety as a clinical outcome among chronic pain participants, the

- 275 pooled SMD was 0.37 with a 95% CI of 0.05-0.69 (Figure 8). The SMD is significantly greater than
- 0, indicating anxiety symptoms among participants following use of DM applications improved more 276
- 277 than the control group. Additionally, a treatment effect greater than 0 was seen in each individual
- 278 study, thus each study concluded that DM applications improve anxiety symptoms compared with controls. Heterogeneity seen within this dataset was high with $I^2 = 88.34\%$ (p=0.02), indicating a 279
- 280 significant effect of the DM applications compared with the control group.
- 281 [FIGURE 6a]
- 282 *Pain interference*
- 283 Four studies reported pain interference, an important outcome in pain research. Figure 6a
- 284 demonstrates a pooled SMD of 0.15 with a 95% CI of -0.05–0.34. SMD was not significantly higher
- than 0, suggesting that the improvement within the treatment group was not significantly greater than 285
- 286 control group. DM applications appear to have no effect on participants exposed to the application
- 287 based on an , indicating mild heterogeneity. Therefore, a lack of a statistically obvious effect has
- 288 been observed within the pooled dataset.
- 289 Fatigue/sleep
- 290 Two studies reported on fatigue and one study on sleep issues. The forest plots for these factors are 291 illustrated below (Figures 6b and 6c).
- 292 [FIGURE 6b]
- 293 [FIGURE 6c]
- 294 The pooled SMD for fatigue was 0.29, indicating the treatment group improved following the
- 295 completion of the DM application use. However, this conclusion is not statistically significant given
- 296 the 95% CI of -0.18-0.76. This could be due to the presence of only 2 studies, and more is needed to
- 297 reach a conclusion.
- 298 The pooled SMD for sleep issues was -0.04 with a 95%CI of -0.4-0.32. This indicates that DM
- 299 applications did not improve sleep-related issues and is of a lower score compared to the control
- 300 group. However, to provide a more comprehensive conclusion to this phenomenon, further studies
- 301 would be required.
- 302

303 Subgroup analysis

Subgroup analysis was conducted to identify the source of raised heterogeneity when considering
 studies reporting on pain intensity. Initial analysis considered the categories of DM applications
 which included web-applications, mobile apps and chatbots. The analysis is demonstrated in Figure
 7.

308 [FIGURE 7]

309 The pooled SMD for web-applications was 0.22, indicating web-applications could reduce the

310 intensity of pain compared to the control group. The pooled SMD of mobile apps was 0.30. This

311 demonstrates a larger effect size in relieving the intensity of pain compared to control groups and to

those using web-applications. The pooled SMD for chatbots was -0.02, indicating chatbots have a

313 limited effect in reducing the intensity of pain in patients compared to the controls. Heterogeneity 314 remained high in all three subgroups, so a second subgroup analysis was conducted based on

314 remained high in all three subgroups, so a second subgroup analysis was conducted based on 315 exposure of pain symptoms. The pain exposure sub-group analysis included identified specific pain

316 conditions: fibromyalgia, back pain, chronic pain, osteoarthritis pain, menstrual pain, and cancer-

317 related pain (Figure 8).

318 [FIGURE 8]

319 Heterogeneity could only be calculated in three of the subgroups. It remained high within these

320 pooled subgroups, although at a lower level compared to previous analyses. Cancer-related pain

321 reported the highest level of heterogeneity ($I^2=92.23\%$). Chronic pain and osteoarthritis pain groups

322 reported an I^2 of 82.44% and 85.19% respectively. However, due to the limited number of studies,

pain and digital application exposures, the effect size could not be comprehensively assessed. A third

324 subgroup analysis was conducted based on geographical locations (Figure 9a and 9b).

- 325 [FIGURE 9a]
- 326 [FIGURE 9b]

327 A sub-group analysis by country found that DM applications appear to be effective within

328 populations in America, China, Germany, and Netherlands, while for Ireland and Norway, a

329 statistically significant effect was lacking. Only mild heterogeneity levels were indicated for America

 $(I^2=61.54\%)$ and Germany ($I^2=45.91\%$). The heterogeneity may well be due to nationality and

- 331 ethnicity.
- 332 Sensitivity analysis

333 Based on the meta-analysis and the sub-group analysis conducted to demonstrate pain intensity

outcomes from the digital tools reported by Anderson et al,⁴⁹ Chiauzzi et al⁴² and Sun et al,³⁴ the

335 standard mean deviation (SMD) was high. The primary populations of Chiauzzi and colleagues

336 (2010) and Anderson and colleagues (2004) were African American followed by Hispanic, whilst

337 Sun et al (2017) reported on a population of Chinese patients. Similar ethnicity and race patterns

were found among 12 of the 15 studies in the meta-analysis. Of these, 5 reported ethnicity, although

- over 50% of the sample size was Caucasian. The other 7 did not provide specific percentages of the
 Caucasian representation. A sensitivity analysis was conducted to assess ethnic variability within the
- pooled sample size, which resulted in a SMD of 0.14 with a 95% CI of -0.07-0.35 (Figure 10).

Running Title

342 [FIGURE 10]

343 The sensitivity analysis reveals DM applications appear to benefit patients. However, to conclusively

344 demonstrate a statistical significance more studies would be required. The *p*-value where the reported

345 SMD was greater than 0 was 0.2, indicating there is a 90% probability that the DM application would

have a positive impact on the patient's pain. It is equally vital to recognize that the predominantly

- African American and Hispanic population-based studies reported a SMD of 0.76 with a 95% of
- 0.48-1.05, and a study consisting entirely of African American and Hispanic participants reported a
 SMD of 0.19 (95%CI -0.21-0.59). Sun et al (2017) reported a SMD of 1.34 with a 95% CI of 0.72-
- 350 1.96. Therefore, DM applications appear to have a positive impact on patients.
- 351 The sensitivity analysis shown in Figure 16 demonstrates strong heterogeneity. The main source of
- 352 heterogeneity could be the difference in the treatment interventions deployed by way of the DM
- 353 application. As this is associated with the interventions themselves rather than the DM applications, it
- is beyond the scope of this study, and could be explored in the future. Pooled SMD of web-
- application, mobile apps and chatbots were 0.22, 0.1 and -0.02 respectively. Figure 11 demonstrates
- that the most effective DM application could be mobile apps since web-applications are not a self-
- 357 reported method.
- 358 [FIGURE 11]
- 359 Publication bias
- 360 Publication bias was assessed and reported using funnel plots and Egger's test to examine the small-

361 study effect. Publication bias appears to be smaller among studies associated with fatigue and sleep,

362 and higher in studies demonstrating pain intensity, depression, anxiety, and pain interferences. There

363 is a lack of significant publication bias based on the funnel plot (Figure 12a, below). The Egger's test

p-value is 0.932, indicating the lack of a small study effect. However, there are 5 studies that fell

365 outside the 95% CI which could affect our detection of publication bias. The *p*-value is not high but it

- is limited by the data and experimental quality.
- 367 [FIGURE 12a]
- 368 [FIGURE 12b]
- 369 [FIGURE 12c]
- 370 [FIGURE 12d]

Figures 12b and 12c indicate a lack of publication bias statistically for depression and anxiety, with

Egger's test *p*-values of 0.838 and 0.712 respectively. Pain inferences (Figure 12d), which was

included in four studies, had an Egger's test *p*-value of 0.43, which demonstrates we cannot detect a

publication bias. The low numbers of studies reporting outcomes for fatigue and sleep problems

- 375 meant analysis of publication bias was not possible.
- 376
- 377
- 378

379 Discussion

The prevalence of DM applications within pain research appear to be moderate and is focused around 380 381 developed countries such as America and Germany. China appears to be the only country within Asia 382 to have conducted a study to assess the use of DM applications among patients with chronic pain. 383 This demonstrates an urgent need to conduct evaluations of these DM applications in low-income 384 and middle-income countries to optimise and evaluate the efficacy and acceptability among patients 385 and clinicians. Patient-reported DM applications identified in the systematic review could be 386 categorised primarily as mobile apps and chatbots, as EHR systems were used to assess pain-387 associated outcomes. As a result of these differences, the prevalence of DM applications was meta-388 analysed at a granular level to identify and report pain outcomes such as depression, anxiety, pain 389 intensity and pain inference that were assessed by the tools. The lack of uniformity among the 390 assessments used within the applications are another issue that requires further elaboration if these 391 are to be used by clinicians as part of a patient's ongoing clinical management. The assessments used 392 also appear to be non-specific to a particular group of patients. Often, the studies did not report on 393 underlying conditions or if the pain conditions had a clinical diagnosis. Thus, it is challenging to 394 demonstrate that users demonstrated true clinical benefit. This suggests there is little quantifiable data 395 to provide a comprehensive conclusion in terms of the generalisability and feasibility of these

396 applications globally.

397 We identified multiple themes and sub-themes in this analysis that were pooled as mobile

398 applications, EHR and chatbots. Mobile applications have grown rapidly to support the management

399 of pain disorders such as migraine, back pain and fibromyalgia by offering educational components,

400 exercise platforms, relaxation techniques and mindfulness-based options to name a few. These

401 options provide feedback and allow engagement and adherence of the users. This may explain why

402 mobile applications demonstrated better results compared with other DM applications in the

403 management of chronic pain. Another facet to consider is the inclusion of these datasets to maintain a 404 structured approach to deliver effective continuity of care provision. Trials promoting the evaluation

405 of data in a comprehensive manner through systems that allow the standardisation and acceptance of

406 quality data would increase the acceptance of digitised data. Trials involving DM applications that

407 incorporate AI-based clinical algorithms to assist with the evaluation of pain and outcomes in

patients with cancer appear encouraging.⁵³ 408

Ledel Solem and colleagues (2019) reported adult participants were in favour of using DM-based 409

self-management interventions for chronic pain management.⁵⁴ Patients felt that the accessibility, 410

411 usability, and personalisation were vital for DM tools, and suggested that these should be further

412 developed to distract them from pain, regardless of pain intensity and cognitive capacity.

413 The benefits of harnessing DM within the context of pain medicine could improve both clinical and

414 patient-reported outcomes. Evidence-gathering to support therapeutic efficacy for pharmacological or

415 surgical treatments requires effective and robust methodology, yet rigid traditional trial designs

416 remain inefficient and struggle with implementation into clinical practice, limiting sustainability

417 within healthcare systems. Computer-based technology could address these obstacles in research. The

418 flexibility and accessibility of digital technology enables a more convenient and improved consenting

419 process. This could allow easier enrolment and participation in studies for populations disadvantaged 420

by mobility or literacy issues. Increased recruitment and retention lead to larger study populations

421 with greater data validity, and aids researchers by speeding up recruitment and assessment of large

422 trial populations.

- Digital clinical trials are key in collating all the above factors, as it is a fundamental tool in assessing 423
- 424 the efficacy and safety of novel drugs, medical devices, and health system interventions. Traditional
- 425 clinical trials have demonstrated the validity, acceptability, and sustainability of the interventions,
- 426 whilst digital clinical trials could leverage technologies to engage and report trial-specific
- measurements associated with the interventions being tested at a lower cost.⁵⁹ Conceptualising digital 427
- 428 clinical trials for pain medicine could have added benefits, especially for patients who could report
- 429 pain episodes daily. That would allow digital analytics to assess considerations clinicians need to
- 430 make when developing clinical treatments. Additionally, data science approaches could be leveraged
- 431 in this instance to develop novel clinical methods to best utilise trial data with 'real-world' data to
- 432 develop aggregated datasets. These could be used to promote multi-morbid clinical research, which is
- 433 vital in furthering clinical practices associated with pain medicine.
- 434 Limitations
- 435 Unified approaches of conducting DM application assessments were lacking across all 3 categories
- 436 identified and reported within the scope of this study. As a result, the pooled analysis conducted
- 437 limits the generalizability of the findings. It is evident that the lack of validation in digital
- 438 applications is another rate-limiting factor in furthering the use of these among clinical populations.

439 Conclusion

- 440 The pain medicine ecosystem has a plethora of research studies, although those in population
- 441 research, prevention, clinical trials, and education, as well as training, need to evolve if
- 442 improvements are to be made clinically. This could integrate evolving DM concepts, including AI
- 443 applications, that could improve patient-reported outcomes. It is, therefore, important to conduct
- 444 further well-designed digital clinical trials.

445 Another concern based on evidence ascertained in this study is the minimal use of clinical trials to 446 test DM applications; therefore, the efficacy and efficiency of these, as well as the generalizability to 447 a wider population, remain limited. Pragmatic and novel methods of conducting clinical trials would 448 be beneficial in providing credible evidence before these DM applications are used within clinical 449 practice. Alternatives such as simulation studies using *real-world* environments could be used to test 450 novel DM applications, given the complexities around conducting pain research. Similarly, it may be 451 beneficial for patients to gain access to DM applications more quickly, especially those managing 452 chronic pain. Therefore, a paradox of "no evidence, no implementation vs. no implementation, no 453 evidence" is a challenge to clinicians, patients, policymakers, and clinical researchers alike. Using 454 simulation methods, where possible, could provide an alternative method to overcome this paradox, 455 although there may be limitations that would need considering as it not always feasible to design 456 precise simulations or perform competency validation. The proliferation of digital technologies 457 would provide the leverage to optimise global care by way of mobile platforms, to open better 458 avenues, and to measure outcome data from wearable devices. These applications use real-world data 459 that could benefit patients and clinicians alike. Thus, the use of DM in pain medicine could promote 460 a myriad of benefits.

- 461
- 462
- 463
- 464

Running	Title
---------	-------

465	
466	
467	References
468	1. Edwards RR, Dworkin RH, Turk DC, Angst MS, Dionne R, Freeman R, et al. Patient
469	phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain
470	2016;157(9):1851-1871. doi:10.1097/j.pain.000000000000000000
471	2. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic
472	pain: controversies, current status, and future directions. <i>Exp Clin Psychopharmacol</i> .
473	2008;16(5):405-416. doi:10.1037/a0013628
474	3. Broderick JE, Schwartz JE, Vikingstad G, Pribbernow M, Grossman S, Stone AA. The
475	accuracy of pain and fatigue items across different reporting periods. Pain. 2008;139(1):146-
4/6	157. doi:10.1016/j.pain.2008.03.024
4//	4. Bolger N, Laurenceau J. Intensive longituainal methoas: An introduction to alary and
470 470	5 Fillingim PR Losser ID Paron P. Edwards PR Assessment of Chronic Pain: Domains
479	J. Thinight RB, Loesel JD, Balon R, Edwards RR. Assessment of Chronic Fail. Domains, Methods, and Mechanisms, <i>I Pain</i> , 2016;17(0 Suppl):T10 T20
481	doi:10.1016/j.ipain.2015.08.010
482	6 Mun CI Suk HW Davis MC Karoly P Finan P Tennen H et al Investigating
483	intraindividual pain variability: methods applications issues and directions <i>Pain</i>
484	2019:160(11):2415-2429. doi:10.1097/i.pain.00000000001626
485	7. World Health Organization. Monitoring and Evaluating Digital Health Interventions: a
486	practical guide to conducting research and assessment.
487	http://apps.who.int/iris/bitstream/handle/10665/252183/9789241511766-
488	eng.pdf;jsessionid=9630003E91620D111417E2CE52AF8075?sequence=1. Accessed 23
489	May, 2021.
490	8. Medicines & Healthcare products Regulatory Agency. Custom-made devices in Great Britair
491	https://www.gov.uk/government/publications/custom-made-medical-devices/custom-made-
492	devices-in-great-britain. Accessed 23 May, 2021.
493	9. U.S. Food and Drug Administration. Factors to Consider Regarding Benefit Risk in Medical
494	Device Product Availability, Compliance, and Enforcement Decisions: Guidance for Industry
495	and Food and Drug Administration Staff.
496	https://www.fda.gov/files/medical%20devices/published/Factors-to-Consider-Regarding-
497	Benefit-Risk-in-Medical-Device-Product-AvailabilityComplianceand-Enforcement-
498	DecisionsGuidance-for-Industry-and-Food-and-Drug-Administration-Staff.pdf. Accessed
499	23 May, 2021.
500	10. National Institute for Health and Care Excellence. Evidence standards framework for digital
501	health technologies. https://www.nice.org.uk/Media/Default/About/what-we-do/our-
502	programmes/evidence-standards-framework/digital-evidence-standards-framework.pdf.
503	Accessed 23 May, 2021.
504	11. Gentili C, Zetterqvist V, Kickardsson J, Holmstrom L, Simons LE, Wicksell RK. ACTsmart:
505 506	Bilot Trial Dain Mad 2021;22(2):215,228, doi:10.1002/am/area260
300	rnot mai. <i>run mea.</i> 2021;22(2):515-528. doi:10.1093/pm/pnaa360

Rui	nning	Title

507	12. Bostrøm K, Børøsund E, Varsi C, Eide H, Nordang EF, Schreurs KM, et al. Digital Self-
508	Management in Support of Patients Living With Chronic Pain: Feasibility Pilot Study. JMIR
509	Form Res. 2020:4(10):e23893. doi:10.2196/23893
510	13. Greenberg J. Popok PJ. Lin A. Kulich RJ. James P. Macklin EA. et al. A Mind-Body Physical
511	Activity Program for Chronic Pain With or Without a Digital Monitoring Device: Proof-of-
512	Concept Feasibility Randomized Controlled Trial. JMIR Form Res. 2020:4(6):e18703.
513	doi:10.2196/18703
514	14. Jonassaint CR, Rao N, Sciuto A, Switzer GE, De Castro L, Kato GJ, et al. Abstract
515	Animations for the Communication and Assessment of Pain in Adults: Cross-Sectional
516	Feasibility Study. J Med Internet Res. 2018:20(8):e10056. doi:10.2196/10056
517	15. van der Heijden AA, Abramoff MD, Verbraak F, van Hecke MV, Liem A, Nijpels G.
518	Validation of automated screening for referable diabetic retinopathy with the IDx-DR device
519	in the Hoorn Diabetes Care System. Acta Ophthalmol. 2018;96(1):63-68.
520	doi:10.1111/aos.13613
521	16. Bossen D, Veenhof C, Van Beek KE, Spreeuwenberg PM, Dekker J, De Bakker DH.
522	Effectiveness of a web-based physical activity intervention in patients with knee and/or hip
523	osteoarthritis: randomized controlled trial. J Med Internet Res. 2013;15(11):e257.
524	doi:10.2196/jmir.2662
525	17. Hedman-Lagerlöf M, Hedman-Lagerlöf E, Axelsson E, Ljótsson B, Engelbrektsson J,
526	Hultkrantz S, et al. Internet-Delivered Exposure Therapy for Fibromyalgia: A Randomized
527	Controlled Trial. Clin J Pain. 2018;34(6):532-542. doi:10.1097/AJP.0000000000000566
528	18. Krein SL, Kadri R, Hughes M, Kerr EA, Piette JD, Holleman R, et al. Pedometer-based
529	internet-mediated intervention for adults with chronic low back pain: randomized controlled
530	trial. J Med Internet Res. 2013;15(8):e181. doi:10.2196/jmir.2605
531	19. Rini C, Porter LS, Somers TJ, McKee DC, DeVellis RF, Smith M, et al. Automated Internet-
532	based pain coping skills training to manage osteoarthritis pain: a randomized controlled trial.
533	Pain. 2015;156(5):837-848. doi:10.1097/j.pain.000000000000121
534	20. Williams DA, Kuper D, Segar M, Mohan N, Sheth M, Clauw DJ. Internet-enhanced
535	management of fibromyalgia: a randomized controlled trial. Pain. 2010;151(3):694-702.
536	doi:10.1016/j.pain.2010.08.034
537	21. Wilson M, Roll JM, Corbett C, Barbosa-Leiker C. Empowering Patients with Persistent Pain
538	Using an Internet-based Self-Management Program. Pain Manag Nurs. 2015;16(4):503-514.
539	doi:10.1016/j.pmn.2014.09.009
540	22. Raj SX, Brunelli C, Klepstad P, Kaasa S. COMBAT study - Computer based assessment and
541	treatment - A clinical trial evaluating impact of a computerized clinical decision support tool
542	on pain in cancer patients. Scand J Pain. 2017;17:99-106. doi:10.1016/j.sjpain.2017.07.016
543	23. Guillory J, Chang P, Henderson Jr CR, Shengelia R, Lama S, Warmington M, et al. Piloting a
544	Text Message-based Social Support Intervention for Patients With Chronic Pain: Establishing
545	Feasibility and Preliminary Efficacy. Clin J Pain. 2015;31(6):548-556.
546	doi:10.1097/AJP.00000000000193
547	24. Berman RL, Iris MA, Bode R, Drengenberg C. The effectiveness of an online mind-body
548	intervention for older adults with chronic pain. J Pain. 2009;10(1):68-79.
549	doi:10.1016/j.jpain.2008.07.006
550	25. Carpenter KM, Stoner SA, Mundt JM, Stoelb B. An online self-help CBT intervention for
551	chronic lower back pain. Clin J Pain. 2012;28(1):14-22. doi:10.1097/AJP.0b013e31822363db

550	26 Manage C. Ing S. Khan O. Dunne B. Dormallag A.C. Alamatric A. et al. Ethnomycalaise and
552	20. Menga G, Ing S, Khan O, Duple B, Donnenes AC, Alarakina A, et al. Fiotomyaigia. Can
555	onnne cognitive benavioral therapy neip? Ochsner J. 2014;14(5):545-549.
554	http://www.ochsnerjournal.org/content/14/3/343. Accessed 15 February, 2022.
555	27. O'moore KA, Newby JM, Andrews G, Hunter DJ, Bennell K, Smith J, et al. Internet
556	Cognitive-Behavioral Therapy for Depression in Older Adults with Knee Osteoarthritis: A
557	Randomized Controlled Trial. Arthritis Care Res (Hoboken). 2018;70(1):61-70.
558	doi:10.1002/acr.23257
559	28. Minen MT, Adhikari S, Seng EK, Jinich S, Powers SW, Lipton RB. Smartphone-based
560	migraine behavioral therapy: a single-arm study with assessment of mental health predictors.
561	NPJ Digit Med. 2019;2:46. doi:10.1038/s41746-019-0116-y
562	29. Toelle TR, Utpadel-Fischler DA, Haas KK, Priebe JA. App-based multidisciplinary back pain
563	treatment versus combined physiotherapy plus online education: a randomized controlled
564	trial. NPJ Digit Med. 2019;2:34. doi:10.1038/s41746-019-0109-x
565	30. Blödt S, Pach D, Eisenhart-Rothe SV, Lotz F, Roll S, Icke K, et al. Effectiveness of app-
566	based self-acupressure for women with menstrual pain compared to usual care: a randomized
567	pragmatic trial. Am J Obstet Gynecol. 2018;218(2):227.e1-227.e9.
568	doi:10.1016/j.ajog.2017.11.570
569	31. Irvine AB, Russell H, Manocchia M, Mino DE, Glassen TC, Morgan R. Mobile-Web app to
570	self-manage low back pain: randomized controlled trial. J Med Internet Res.
571	2015:17(1):e3130. doi:10.2196/imir.3130
572	32. Schatz J. Schlenz AM, McClellan CB, Puffer ES, Hardy S, Pfeiffer M, et al. Changes in
573	coping pain and activity after cognitive-behavioral training, a randomized clinical trial for
574	pediatric sickle cell disease using smartphones <i>Clin I Pain</i> 2015:31(6):536-547
575	doi:10.1097/AIP.0000000000183
576	33 Skrepnik N Spitzer A Altman R Hoekstra I Stewart I Toselli R Assessing the Impact of a
570 577	Novel Smartnhone Application Compared With Standard Follow-Up on Mobility of Patients
578	With Knop Ostoosethritis Following Treatmont With Hylen G E 20: A Pondomized
570	Controlled Trial IMIP Mhealth Uhealth 2017;5(5):664 doi:10.2106/mhealth 7170
519	24 Sup V. Hong F. Cu. H. Wong VK. Hug H. Li L et al. Development and Testing of an
J8U 591	54. Sun Y, Jiang F, Gu JJ, Wang YK, Hua H, Li J, et al. Development and Testing of an
581	Interrigent Pain Management System (IPMS) on Mobile Phones Infough a Randomized Inal
582	Among Chinese Cancer Patients: A New Approach in Cancer Pain Management. <i>JMIR</i>
583	Mhealth Uhealth. 2017;5(7):e108. doi:10.2196/mhealth.7178
584	35. Guetin S, Brun L, Deniaud M, Clerc JM, Thayer JF, Koenig J. Smartphone-based Music
585	Listening to Reduce Pain and Anxiety Before Coronarography: A Focus on Sex Differences.
586	Altern Ther Health Med. 2016;22(4):60-63.
587	36. Jamison RN, Jurcik DC, Edwards RR, Huang CC, Ross EL. A Pilot Comparison of a
588	Smartphone App With or Without 2-Way Messaging Among Chronic Pain Patients: Who
589	Benefits From a Pain App? Clin J Pain. 2017;33(8):676-686.
590	doi:10.1097/AJP.00000000000455
591	37. Jibb LA, Stevens BJ, Nathan PC, Seto E, Cafazzo JA, Johnston DL, et al. Implementation and
592	preliminary effectiveness of a real-time pain management smartphone app for adolescents
593	with cancer: A multicenter pilot clinical study. Pediatr Blood Cancer. 2017;64(10):e26554.
594	doi:10.1002/pbc.26554
595	38. Lee M, Lee SH, Kim T, Yoo HJ, Kim SH, Suh DW. Feasibility of a Smartphone-Based
596	Exercise Program for Office Workers With Neck Pain: An Individualized Approach Using a

597	Self-Classification Algorithm Arch Phys Med Rehabil 2017.98(1).80-87
598	doi:10.1016/j.apmr.2016.09.002
599	39. Oldenmenger WH, Witkamp FE, Bromberg JE, Jongen JL, Lieverse PI, Huygen EI, et al. To
600	be in pain (or not): a computer enables outpatients to inform their physician. Ann Oncol
601	2016:27(9):1776-1781. doi:10.1093/annonc/mdw250
602	40. Huber S. Priebe JA. Baumann KM. Plidschun A. Schiessl C. Tölle TR. Treatment of Low
603	Back Pain with a Digital Multidisciplinary Pain Treatment App: Short-Term Results. JMIR
604	<i>Rehabil Assist Technol.</i> 2017;4(2):e11. doi:10.2196/rehab.9032
605	41. Calner T, Nordin C, Eriksson MK, Nyberg L, Gard G, Michaelson P. Effects of a self-guided,
606	web-based activity programme for patients with persistent musculoskeletal pain in primary
607	healthcare: A randomized controlled trial. Eur J Pain. 2017;21(6):1110-1120.
608	doi:10.1002/ejp.1012
609	42. Chiauzzi E, Pujol LA, Wood M, Bond K, Black R, Yiu E, et al. painACTION-back pain: a
610	self-management website for people with chronic back pain. Pain Med. 2010;11(7):1044-
611	1058. doi:j.1526-4637.2010.00879.x
612	43. Davis MC, Zautra AJ. An online mindfulness intervention targeting socioemotional
613	regulation in fibromyalgia: results of a randomized controlled trial. Ann Behav Med.
614	2013;46(3):273-284. doi:10.1007/s12160-013-9513-7
615	44. Dowd H, Hogan MJ, McGuire BE, Davis MC, Sarma KM, Fish RA, et al. Comparison of an
616	Online Mindfulness-based Cognitive Therapy Intervention With Online Pain Management
617	Psychoeducation: A Randomized Controlled Study. Clin J Pain. 2015;31(6):517-527.
618	doi:10.1097/AJP.000000000000000000000000000000000000
619	45. Lin J, Wurst R, Paganini S, Hohberg V, Kinkel S, Göhner W, et al. A group- and smartphone-
620	based psychological intervention to increase and maintain physical activity in patients with
621	musculoskeletal conditions: study protocol for a randomized controlled trial ("MoVo-App").
622	Trials. 2020;21(1):502. doi:10.1186/s13063-020-04438-4
623	46. Nordin CA, Michaelson P, Gard G, Eriksson MK. Effects of the Web Behavior Change
624	Program for Activity and Multimodal Pain Rehabilitation: Randomized Controlled Trial. J
625	Med Internet Res. 2016;18(10):e265. doi:10.2196/jmir.5634
626	47. Ruehlman LS, Karoly P, Enders C. A randomized controlled evaluation of an online chronic
627	pain self management program. Pain. 2012;153(2):319-330. doi:10.1016/j.pain.2011.10.025
628	48. Ström L, Pettersson R, Andersson G. A controlled trial of self-help treatment of recurrent
629	headache conducted via the Internet. J Consult Clin Psychol. 2000;68(4):722-727.
630	doi:10.1037/0022-006x.68.4.722
631	49. Anderson KO, Mendoza TR, Payne R, Valero V, Palos GR, Nazario A, et al. Pain education
632	for underserved minority cancer patients: a randomized controlled trial. <i>J Clin Oncol</i> .
633	2004;22(24):4918-4925. doi:10.1200/JCO.2004.06.115
634	50. Lovell MR, Forder PM, Stockler MR, Butow P, Briganti EM, Chye R, et al. A randomized
635	controlled trial of a standardized educational intervention for patients with cancer pain. J Pain
636 627	Symptom Manage. 2010;40(1):49-59. doi:10.1016/j.jpainsymman.2009.12.013
03/	51. Guetin S, Brun L, Meriadec C, Camus E, Deniaud M, Thayer JF, et al. A Smartphone-Based
038 620	Nusic intervention to Reduce Pain and Anxiety in women before or during labor. <i>EuJIM</i> .
039	2010,21.24-20. doi:10.1010/j.eujiii.2018.00.001

- 640 52. Oldenmenger WH, Baan MAG, van der Rijt CCD. Development and feasibility of a web 641 application to monitor patients' cancer-related pain. Support Care Cancer. 2018;26(2):635-642 642. doi:10.1007/s00520-017-3877-3 643 53. Kamdar M, Centi AJ, Agboola S, Fischer N, Rinaldi S, Strand JJ, et al. A randomized 644 controlled trial of a novel artificial intelligence-based smartphone application to optimize the management of cancer-related pain. J Clin Onc. 2019;37:11514. 645 doi:10.1200/JCO.2019.37.15_suppl.11514 646 647 54. Solem IK, Varsi C, Eide H, Kristjansdottir OB, Mirkovic J, Børøsund E, et al. Patients' Needs and Requirements for eHealth Pain Management Interventions: Qualitative Study. J Med 648 649 Internet Res. 2019;21(4):e13205. doi:10.2196/13205 650 55. Witzeman K, Flores OA, Renzelli-Cain RI, Worly B, Moulder JK, Carrillo JF, et al. Patient-651 Physician Interactions Regarding Dyspareunia with Endometriosis: Online Survey Results. J 652 Pain Res. 2020;13:1579-1589. doi:10.2147/JPR.S248887 56. McConnell MV, Shcherbina A, Pavlovic A, Homburger JR, Goldfeder RL, Waggot D, et al. 653 654 Feasibility of Obtaining Measures of Lifestyle From a Smartphone App: The MyHeart Counts 655 Cardiovascular Health Study. JAMA Cardiol. 2017;2(1):67-76. 656 doi:10.1001/jamacardio.2016.4395 57. Urteaga I, McKillop M, Elhadad N. Learning endometriosis phenotypes from patient-657 658 generated data. NPJ Digit Med. 2020;3:88. doi:10.1038/s41746-020-0292-9 58. Jacobson NC, Summers B, Wilhelm S. Digital Biomarkers of Social Anxiety Severity: Digital 659 660 Phenotyping Using Passive Smartphone Sensors. J Med Internet Res. 2020;22(5):e16875. 661 doi:10.2196/16875 662 59. Inan OT, Tenaerts P, Prindiville SA, Reynolds HR, Dizon DS, Cooper-Arnold K, et al. 663 Digitizing clinical trials. NPJ Digit Med. 2020;3(101):1-7. doi:10.1038/s41746-020-0302-y
- 60. Guo C, Ashrafian H, Ghafur S, Fontana G, Gardner C, Prime M. Challenges for the 664 665 evaluation of digital health solutions-A call for innovative evidence generation approaches. 666 NPJ Digit Med. 2020;3:110. doi:10.1038/s41746-020-00314-2
- 667

668 Acknowledgments

- 669 This paper is part of the multifaceted ELEMI project that is sponsored by Southern Health NHS
- 670 Foundation Trust and in collaboration with the University of Liverpool, University College London,
- 671 University College London NHS Foundation Trust, Liverpool Women's Hospital, University of
- 672 Southampton, Robinson Institute-University of Adelaide, Ramaiah Memorial Hospital (India),
- 673 University of Geneva and Manchester University NHS Foundation Trust.
- 674 This paper is also part of the POP project focusing on Chronic Pain that is sponsored by University
- 675 College London NHS Foundation Trust and in collaboration with University of Oxford and
- 676 University of Southampton.

677 Funding

- 678 GD, and PP are supported by National Institute for Health Research (NIHR) Research Capability
- 679 Funding (RCF) and by Southern Health NHS Foundation Trust. AS is supported by industry funding.
- 680 **Author Contributions**

- 681 GD conceptualised the logic model of this paper and developed the systematic methodology. GD and
- 682 AS wrote the first draft of the manuscript. The systematic methodology was critically appraised by
- AS and GD initially. RE, GD and AS extracted the data. This data was reviewed by GD and AS. GD, 683
- JS and YZ developed the statistical analysis plan. JS, YZ, GD, TF and AS conducted the full 684
- analysis. The full paper was critically appraised by all authors. All authors approved the final version 685
- of the manuscript. 686

687 **Conflict of Interest**

- 688 PP has received research grant from Novo Nordisk, and other, educational from Queen Mary
- University of London, other from John Wiley & Sons, other from Otsuka, outside the submitted 689
- 690 work. SR reports other from Janssen, 691 Lundbeck and Otsuka outside the submitted work. All
- 691 other authors report no conflict of interest.
- 692 TF has received funding from Boston Scientific. AS is the Chief Medical Officer for Nurokor 693 Medical Systems.
- 694 The views expressed are those of the authors and not necessarily those of the NHS, the National
- 695 Institute for Health Research, the Department of Health and Social Care or the Academic institutions.

696 **Data Availability Statement**

- 697 All data used within this study has been publicly available. The authors will consider sharing the
- dataset gathered upon request. 698

699

700 **Figure legends**

- 701 Figure 1: Chronic Pain Classification Tree (CPCT)
- 702 Figure 2: Acute Pain Classification Tree
- 703 Figure 3: Representation of the PRISMA Flowchart
- 704 Figure 4: AMSTAR assessment
- 705 Figure 5a: Forest plot of pain intensity
- 706 Figure 5b: Forest plot of depression
- 707 Figure 5c: Forest plot for anxiety
- 708 Figure 6a: Forest plot for pain interference
- 709 Figure 6b: Forest plot of fatigue
- 710 Figure 6c: Forrest plot of sleep
- 711 Figure 7: Subgroup analysis for pain intensity (web-application, mobile apps, chatbots)
- 712 Figure 8: Subgroup analysis for pain intensity (by pain type)
- Figure 9a: Subgroup analysis for pain intensity (by country) 713
- Figure 9b: Geographical spread of data collected for the systematic review Figure 10: Sensitivity analysis without 3 BAME studies^{31,39,58} 714
- 715
- Figure 11: Sensitivity analysis without 3 BAME studies^{31,39,58} (sub-grouped by digital applications) 716
- Figure 12a: Funnel plot for pain intensity & Egger's test for pain intensity 717
- Figure 12b: Funnel plot for depression & Egger's test for depression 718
- 719 Figure 12c: Funnel plot for anxiety & Egger's test for anxiety
- 720 Figure 12d: Funnel plot for pain inferences & Egger's test for pain inferences
- 721
- 722

Running Title

723 Tables

724 Table 1. Characteristics of the systematically included studies

Author	Diagnosis/Treatment method	Digital application and method of application delivery	Study type	Sample size	Country	Exposure
Bossen et al (2013)	Intervention	Web-based intervention	RCT	199	Netherlands	osteoarthritis pain
Hedman- Lagerlöf, et al (2018)	Intervention	Web-based intervention	RCT	140	Sweden	fibromyalgia
Krein et al (2013)	Intervention	Web-based intervention	RCT	229	USA	chronic low back pain
Rini et al (2015)	Intervention	Web-based intervention	RCT	113	USA	osteoarthritis pain
Williams et al (2010)	Intervention	Web-based intervention	RCT	118	USA	fibromyalgia
Wilson et al (2015)	Intervention	Web-based intervention	RCT	92	USA	chronic noncancer pain
Raj et al (2017)	Intervention	Web-based intervention	RCT	214	Norway	cancerrelated pain
Guillory et al (2015)	Chatbots	Text message and mobile app	RCT Feasibility	68	USA	chronic noncancer pain

Berman et al (2009)	t al Chatbots Web inter		RCT	78	USA	chronic pain
Carpenter et al (2012)	Chatbots- Cognitive behavioral therapy with chapters	Web-based intervention	RCT Pilot	141	USA	chronic low back pain
Menga et al (2014)	Chatbots- Cognitive behavioral therapy with chapters	Web-based intervention	RCT	44	USA	Fibromyalgia
O'moore et al (2018)	Chatbots- Cognitive behavioral therapy with chapters	Web-based intervention	RCT	69	USA	osteoarthritis pain
Gentili et al (2020)	Mobile app based acceptance therapy	Mobile based intervention	RCT pilot	31	Sweden	chronic pain
Minen et al (2019)	Mobile app based behavioral therapy	Mobile based intervention	Crosssectional - Feasibility	51	USA	migraine
Toelle et al (2019)	Mobile app based therapy	Mobile based intervention	RCT	94	Germany	Chronic nonspecific low back pain
Blödt et al (2018)	Mobile app based self-acupressure	Mobile based intervention	RCT - Pragmatic	221	Germany	menstrual pain
Irvine et al	Mobile app based	Mobile based	RCT	597	USA	chronic low

(2015)	self-management	intervention				back pain
Schatz et al (2015)	Mobile app based coping, pain and activity	Mobile based intervention	RCT	46	USA	chronic pain for paediatric sickle cell
Nebojsa et al (2017)	Mobile app and an wearable activity monitor	Mobile based intervention	RCT	211	USA	osteoarthritis pain
Sun et al (2017)	Mobile app for pain management	Mobile based intervention	RCT	46	China	cancer-related pain
Guétin et al (2016)	Mobile app delivering music therapy for pain	Mobile based intervention	RCT	106	France	chronic pain
Jamison et al (2017)	Mobile app based daily assessment and treatment	Mobile based intervention	RCT - pilot	90	USA	chronic pain
Jibb et al (2017)	Mobile apps	Mobile based intervention	RCT - pragmatic	40	Canada	cancer-related chronic pain among the adolescent
Lee et al (2017)	Mobile app-based exercise program	Mobile based intervention	Crosssection single group repeated measure	23	Korea	neck pain
Oldenmenger et al (2016)	Mobile apps	Web-based intervention	quantitative	48	Netherlands	cancer-related pain

Huber et al (2017)	Mobile app and EHR	Mobile based intervention	Retrospective RCT	180	Germany	chronic low back pain
Calner et al (2017)	Intervention	Web-based intervention	RCT	109	Sweden	musculoskeletal pain
Chiauzzi et al (2010)	Intervention - self- management	Web-based intervention	RCT	199	USA	chronic pain
Davis et al (2013)	Intervention of mindfulness	Web-based intervention	RCT	79	USA	fibromyalgia
Dowd et al (2015)	Online mindfulness- based cognitive therapy intervention	Web-based intervention	RCT	124	Ireland	chronic pain
Lin et al (2020)	Mobile apps	Web-based intervention	RCT	302	Germany	multimodal pain
Nordin et al (2016)	Intervention for web behaviour change	Web-based intervention	RCT	109	Sweden	Multimodal pain
Ruehlmana et al (2012)	Intervention self- management	Web-based intervention	RCT	305	USA	chronic pain
Ström et al (2000)	Intervention – self- management	Web-based intervention	RCT	45	Sweden	recurrent headache
Anderson et al (2004)	Intervention - video and booklet	Web-based intervention	RCT	97	USA	Cancer-related pain

Running Title

Lovell et al (2010)	Intervention – video and booklet	Web-based intervention	RCT	217	Australia	Cancer-related pain
Guétin et al (2018)	Smartphone-based intervention	Mobile- based intervention	RCT	62	France	chronic painful conditions
Oldenmenger et al (2018)	Intervention – internet applications	Web-based intervention	cohort study	84	Netherlands	Cancer-related pain

725 *EHR = Electronic Health Records; RCT = Randomised clinical trial

726

Table 2. Studies included within the meta-analysis 727

Study ID	Author	Digital applications	Study type	Sample size	Country	Exposure	P-value
1	Bossen et al (2013)	web- application	RCT	199	Netherlands	osteoarthritis pain	0.33 (pain intensity); 0.09 (depression); 0.007 (anxiety)
2	Hedman- Lagerlöf et al (2018)	web- application	RCT	140	Sweden	fibromyalgia	<0.001 (depression); <0.001 (anxiety); <0.001(fatigue)
3	Rini et al (2015)	web- application	RCT	113	USA	osteoarthritis pain	Not provided
4	Williams et al (2010)	web- application	RCT	118	USA	fibromyalgia	Not provided
5	Wilson et	web-	RCT	92	USA	chronic	0.22 (pain intensity); 0.25

<u> </u>	al (2015)	application	1	1		nonconcor noin	(dapression)
	al (2015)	application				noncancer pain	(depression)
6	Raj et al (2017)	web- application	RCT	214	Norway	cancer-related pain	Not provided
7	Berman et al (2019)	chatbots	RCT	78	USA	chronic pain	Not provided
8	Menga et al (2014)	chatbots	RCT	44	USA	Fibromyalgia	0.005 (severity of fibromyalgia)
9	O'moore et al (2018)	chatbots	RCT	69	Australia	osteoarthritis pain	Not provided
10	Gentili et al (2020)	Mobile apps	RCT	94	Germany	chronic low back pain	0.021(pain intensity)
11	Blödt et al (2018)	Mobile apps	RCT	221	Germany	menstrual pain	0.026 (pain intensity)
12	Schatz et al (2015)	Mobile apps	RCT	46	USA	chronic pain	0.1 (negative affect)
13	Sun et al (2017)	Mobile apps	RCT	46	China	cancer-related pain	<0.01 (pain intensity)
14	Calner et al (2017)	Mobile apps	RCT	109	USA	musculoskeletal pain	0.37 (intensity)
15	Chiauzzi et al (2010)	Mobile apps	RCT	199	USA	chronic pain	Not provided
16	Dowd et al (2015)	Mobile apps	RCT	124	Ireland	chronic pain	Not provided
17	Lin et al (2020)	Mobile apps	RCT	302	Germany	multimodal pain	0.01 (pain intensity); <0.01 (depression); 0.44 (anxiety);

Running Title

							<0.01 (pain interference)
18	Ruehlmana et al (2012)	Mobile apps	RCT	305	USA	chronic pain	0.2 (pain intensity); 0.06 (depression); 0.15 (anxiety); 0.3 (pain interference)
19	Ström et al (2000)	Mobile apps	RCT	45	Sweden	recurrent headache	Not provided
20	Anderson et al (2004)	web- application	RCT	84	Netherlands	Cancer-related pain	Not provided

728

729

730 Table 3. Risk of bias, according to the revised risk-of-bias tool for randomised trials (RoB 2.0)

Author	Randomisation process	Deviations from the intended interventions	Missing Outcome Data	Measurement of the Outcome	Selection of the reported result	Overall
Bossen et al (2013)	some concerns*	low risk	low risk	low risk	low risk	some concerns
Hedman- Lagerlöf, et al (2018)	low risk	low risk	low risk	low risk	low risk	low risk
Krein et al (2013)	low risk	low risk	low risk	low risk	low risk	low risk
Rini et al (2015)	low risk	low risk	low risk	low risk	low risk	low risk
Williams et al (2010)	low risk	low risk	low risk	low risk	low risk	low risk
Wilson et al	low risk	low risk	low risk	low risk	low risk	low risk

(2015)						
Raj et al (2017)	low risk	low risk	low risk	low risk	low risk	low risk
Guillory et al (2015)	low risk	low risk	low risk	low risk	low risk	low risk
Berman et al (2009)	low risk	low risk	low risk	low risk	low risk	low risk
Carpenter et al (2012)	low risk	low risk	low risk	low risk	low risk	low risk
Menga et al (2014)	low risk	low risk	low risk	low risk	low risk	low risk
O'moore et al (2018)	low risk	low risk	low risk	low risk	low risk	low risk
Gentili et al (2020)	low risk	low risk	low risk	low risk	low risk	low risk
Minen et al	high risk**	low risk	low risk	low risk	low risk	high risk
(2019)						
(2019) Toelle et al (2019)	some concerns***	low risk	low risk	low risk	low risk	some concerns
Toelle et al (2019) Blödt et al (2018)	some concerns*** low risk	low risk low risk	low risk low risk	low risk low risk	low risk low risk	some concerns low risk
Toelle et al (2019) Blödt et al (2018) Irvine et al (2015)	some concerns*** low risk low risk	low risk low risk low risk	low risk low risk low risk	low risk low risk low risk	low risk low risk low risk	some concerns low risk low risk
Toelle et al (2019) Blödt et al (2019) Irvine et al (2015) Schatz et al (2015)	some concerns*** low risk low risk low risk	low risk low risk low risk low risk	low risk low risk low risk low risk	low risk low risk low risk low risk	low risk low risk low risk low risk	some concerns low risk low risk low risk
Toelle et al (2019) Blödt et al (2019) Blödt et al (2018) Irvine et al (2015) Schatz et al (2015) Nebojsa et al (2017)	some concerns*** low risk low risk low risk low risk	low risk low risk low risk low risk low risk	low risk low risk low risk low risk low risk	low risk low risk low risk low risk low risk	low risk low risk low risk low risk low risk	some concerns low risk low risk low risk
Toelle et al (2019) Blödt et al (2019) Blödt et al (2018) Irvine et al (2015) Schatz et al (2015) Nebojsa et al (2017) Sun et al (2017)	some concerns*** low risk low risk low risk low risk low risk	low risk low risk low risk low risk low risk low risk	low risk low risk low risk low risk low risk	low risk low risk low risk low risk low risk low risk	low risk low risk low risk low risk low risk	some concerns low risk low risk low risk low risk
Toelle et al (2019) Blödt et al (2019) Blödt et al (2018) Irvine et al (2015) Schatz et al (2015) Nebojsa et al (2017) Sun et al (2017) Guétin et al (2016)	some concerns*** low risk low risk low risk low risk low risk low risk	low risk low risk low risk low risk low risk low risk low risk	low risk low risk low risk low risk low risk low risk	low risk low risk low risk low risk low risk low risk low risk	low risk low risk low risk low risk low risk low risk	some concerns low risk low risk low risk low risk low risk

(2017)						
Jibb et al (2017)	low risk	low risk	low risk	low risk	low risk	low risk
Lee et al (2017)	high risk**	low risk	low risk	low risk	low risk	high risk
Oldenmenger et al (2016)	low risk	low risk	low risk	low risk	low risk	low risk
Huber et al (2017)	low risk	low risk	low risk	low risk	low risk	low risk
Calner et al (2017)	low risk	low risk	low risk	low risk	low risk	low risk low risk
Chiauzzi et al (2010)	low risk	low risk	low risk	low risk	low risk	low risk
Davis et al (2013)	low risk	low risk	low risk	low risk	low risk	low risk
Dowd et al (2015)	low risk	low risk	low risk	low risk	low risk	low risk
Lin et al (2020)	low risk	low risk	low risk	low risk	low risk	low risk
Nordin et al (2016)	low risk	low risk	low risk	low risk	low risk	low risk
Ruehlmana et al (2012)	low risk	low risk	low risk	low risk	low risk	low risk
Ström et al (2000)	low risk	low risk	low risk	low risk	low risk	low risk
Anderson et al (2004)	low risk	low risk	low risk	low risk	low risk	low risk
Lovell et al (2010)	low risk	low risk	low risk	low risk	low risk	low risk
Guétin et al (2018)	low risk	low risk	low risk	low risk	low risk	low risk

Running Title

Oldenmenger et al (2018)	high risk**	low risk	low risk	low risk	low risk	high risk

731 * Some concerns due to missing information regarding the allocation concealment.

732 733

** High risk because of lack of randomisation.
*** Some concerns due to deviation from the protocol resulting in a 53:48 distribution of participants.





Figure 4. Mathematical model for data analysis

$$\begin{aligned} x_{e}^{0} \sim \mathcal{N}(m_{e}^{0}, s_{e}^{0^{2}}) \\ x_{e}^{1} \sim \mathcal{N}(m_{e}^{1}, s_{e}^{1^{2}}) \\ x_{c}^{0} \sim \mathcal{N}(m_{c}^{0}, s_{c}^{0^{2}}) \\ x_{c}^{1} \sim \mathcal{N}(m_{c}^{1}, s_{c}^{1^{2}}) \end{aligned}$$

Figure 6. Forest plot of pain intensity

Study of pain intensity Sar	nple siz	e Country I	Digital applications	s Type of pain				Effect Siz with 95%	ze Cl	Weight (%)
Yunheng Sun et al	46	China	mobile apps	cancer related pain	1		_	— 1.34 [0.72,	1.96]	4.90
Rebecca L.H.Berman et al	78	USA	chatbots	chronic pain				-0.02 [-0.47,	0.42]	6.13
Charlotte Gentili et al	94	Germany	mobile apps	back pain		-		0.20 [-0.22,	0.63]	6.24
Dowd, H et al	124	Ireland	mobile apps	chronic pain	_	-		-0.52 [-0.94,	-0.09]	6.28
T. Calner et al	109	USA	mobile apps	osteoarthritis pain	_	-		0.08 [-0.34,	0.50]	6.33
Wilson M et al	92	USA	web-application	chronic pain	-			0.16 [-0.25,	0.57]	6.38
Karen Anderson et al	97	USA	web-application	cancer related pain	1	_		0.19 [-0.21,	0.59]	6.46
Christine Rini et al	113	USA	web-application	osteoarthritis pain	-	-		0.10 [-0.27,	0.47]	6.67
David A. Williams et al	118	USA	web-application	fibromyalgia		_	-	0.38 [0.02,	0.75]	6.72
Daniël Bossen et al	199	Netherlands	web-application	osteoarthritis pain		-	-	0.86 [0.55,	1.16]	7.13
Emil Chiauzzi et al	199	USA	mobile apps	chronic pain		-	-	0.76 [0.48,	1.05]	7.27
Sunil X. Raj et al	214	Norway	web-application	cancer related pain	n —	-		-0.38 [-0.66,	-0.10]	7.29
Jiaxi Lin et al	201	Germany	mobile apps	chronic pain		-		0.13 [-0.14,	0.41]	7.30
Susanne Blödt et al	221	Germany	mobile apps	menstrual pain			-	0.50 [0.23,	0.76]	7.38
Linda S.Ruehlmana et al	305	USA	mobile apps	chronic pain				0.09 [-0.15,	0.33]	7.52
Overall						•		0.25 [0.03,	0.46]	
Heterogeneity: $\tau^2 = 0.14$, I^2	= 82.86	5%, H ² = 5.83								
Test of $\theta_i = \theta_j$: Q(14) = 81.6	7, p = (0.00								
Test of θ = 0: z = 2.25, p =	0.02									
					-1	ò	1	2		
Random-effects DerSimonia Sorted by: _meta_se	n-Laird	model								

Figure 7. Forrest plot of depression

Study of Depression Sample	a siza	Country	Digital applications	Type of pain		Effect Size	Weight
Olday of Depression Compile	5 5120	Country	Digital applications			With 50% Of	(70)
Lasse Strijm et al	45	Sweden	mobile apps	recurrent headcahe		0.21 [-0.42, 0.83]	3.85
Kathleen A. O'moore et al	69	Australia	chatbots	osteoarthritis pain		0.82 [0.32, 1.32]	5.56
Dowd, H et al	124	Ireland	mobile apps	chronic pain		0.19 [-0.30, 0.68]	5.81
Rebecca L.H.Berman et al	78	USA	chatbots	chronic pain		0.22 [-0.23, 0.66]	6.68
Wilson M et al	92	USA	web-application	chronic noncancer pain	n —	0.15 [-0.25, 0.56]	7.57
David A. Williams et al	118	USA	web-application	fibromyalgia		-0.06 [-0.42, 0.30]	9.02
Hedman-Lagerlöf, Maria et al	140	Sweden	web-application	fibromyalgia		0.42 [0.08, 0.75]	10.04
Daniël Bossen et al	199	Netherlands	web-application	osteoarthritis pain		0.39 [0.09, 0.69]	11.37
Emil Chiauzzi et al	199	USA	mobile apps	chronic pain		0.59 [0.31, 0.87]	12.32
Jiaxi Lin et al	201	Germany	mobile apps	multimodal pain		0.23 [-0.05, 0.51]	12.47
Linda S.Ruehlmana et al	305	USA	mobile apps	chronic pain		0.16 [-0.06, 0.39]	15.31
Overall					•	0.30 [0.17, 0.43]	
Heterogeneity: $\tau^2 = 0.02$, $I^2 = 3$	4.72%	, H ² = 1.53					
Test of $\theta_i = \theta_i$: Q(10) = 15.32,	o = 0.1	2					
Test of θ = 0: z = 4.42, p = 0.0	0						
					5 0 .5 1	1.5	
Random-effects DerSimonian-L Sorted by: _meta_se	aird m	odel					



			_								Effect Size	Weight	t
Study of anxiety	Sample s	ize	Country	Digital applications	Type of pain						with 95% CI	(%)	_
Dowd, H et al	1	24	Ireland	mobile apps	chronic pain		-				0.06 [-0.46, 0.58	9.57	
Rebecca L.H.Berman	et al	78	USA	chatbots	chronic pain		_	-			0.27 [-0.18, 0.7] 10.27	
Christine Rini et al	1	13	USA	web-application	osteoarthritis pain	_	-	_			0.04 [-0.33, 0.4] 10.96	
David A. Williams et al	1	18	USA	web-application	fibromyalgia	_	-	_			0.06 [-0.31, 0.42] 11.03	
Hedman-Lagerlöf, Mar	ria et al 1	40	Sweden	web-application	fibromyalgia		_				0.40 [0.07, 0.73] 11.27	
Daniël Bossen et al	1	99	Netherlands	web-application	knee/hip osteoarthritis pain	1		_	-		0.78 [0.48, 1.08] 11.51	
Emil Chiauzzi et al	1	99	USA	mobile apps	chronic pain				_		1.38 [1.10, 1.67] 11.63	
Jiaxi Lin et al	2	01	Germany	mobile apps	multimodal pain			_			0.11 [-0.17, 0.39] 11.71	
Linda S.Ruehlmana	3	05	USA	mobile apps	chronic pain		-	_			0.16 [-0.06, 0.39] 12.07	
Overall							-				0.37 [0.05, 0.69]	
Heterogeneity: $\tau^2 = 0.2$	21, I ² = 88.3	34%,	$H^2 = 8.58$										
Test of $\theta_i = \theta_j$: Q(8) = 6	68.62, p = 0	0.00											
Test of θ = 0: z = 2.28,	p = 0.02												
						5	ò	.5	1	1.5			
Random-effects DerSim Sorted by: _meta_se	nonian-Laire	d mo	odel										



Study of pain intensity Sa	ample	siz@ountryDi	gital applicatio	ns Type of pain				Effe with	ct Size 95% Cl	Weight (%)
Rebecca L.H.Berman et al	78	USA	chatbots	choronic pain	-	-		0.10 [-	0.35, 0.54]	15.62
Dowd, H et al	124	Ireland	mobile apps	chronic pain			_	-0.16 [-	0.58, 0.26]	17.06
Jiaxi Lin et al	201	Germany	mobile apps	multimodal pain				0.36 [0.08, 0.63]	30.89
Linda S.Ruehlmana	305	USA	mobile apps	Chronic pain				0.14 [-	0.10, 0.38]	36.43
Overall						-		0.15 [-	0.05, 0.34]	
Heterogeneity: $\tau^2 = 0.01$, I^2	= 30.5	1%, H ² = 1.4	14							
Test of $\theta_i = \theta_j$: Q(3) = 4.32,	p = 0.2	23								
Test of θ = 0: z = 1.49, p = 0	0.14									
					5	0	.5	1		
Random-effects DerSimonian Sorted by: _meta_se	n-Laird	model								





Figure 11. Forrest plot of sleep



Figure 12 Subgroup analysis for pain intensity (web-application, mobile apps, chatbots)

Study of pain intensity		Effect Size with 95% CI	Weight (%)
chatbots			
Rebecca L.H.Berman et al		-0.02 [-0.47, 0.42]	6.13
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$		-0.02 [-0.47, 0.42]	
Test of θ_i = θ_j : Q(0) = 0.00, p = .			
mobile apps			
Yunheng Sun et al		- 1.34 [0.72, 1.96]	4.90
Charlotte Gentili et al		0.20 [-0.22, 0.63]	6.24
Dowd, H et al		-0.52 [-0.94, -0.09]	6.28
T. Calner et al		0.08 [-0.34, 0.50]	6.33
Emil Chiauzzi et al		0.76 [0.48, 1.05]	7.27
Jiaxi Lin et al		0.13 [-0.14, 0.41]	7.30
Susanne Blödt et al	-	0.50 [0.23, 0.76]	7.38
Linda S.Ruehlmana et al		0.09 [-0.15, 0.33]	7.52
Heterogeneity: τ ² = 0.15, I ² = 83.79%, H ² = 6.17	-	0.30 [0.00, 0.60]	
Test of $\theta_i = \theta_j$: Q(7) = 43.20, p = 0.00			
web-application			
Wilson M et al		0.16 [-0.25, 0.57]	6.38
Karen Anderson et al		0.19[-0.21, 0.59]	6.46
Christine Rini et al		0.10[-0.27, 0.47]	6.67
David A. Williams et al		0.38 [0.02, 0.75]	6.72
Daniël Bossen et al		0.86 [0.55, 1.16]	7.13
Sunil X. Raj et al		-0.38 [-0.66, -0.10]	7.29
Heterogeneity: τ ² = 0.19, I ² = 86.15%, H ² = 7.22	-	0.22 [-0.16, 0.60]	
Test of $\theta_i = \theta_j$: Q(5) = 36.10, p = 0.00			
Overall	•	0.25 [0.03, 0.46]	
Heterogeneity: $\tau^2 = 0.14$, $I^2 = 82.86\%$, $H^2 = 5.83$		anna airdeoi — Starporpraan (airDCDDae)	
Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00			
Test of group differences: $Q_b(2) = 1.41$, p = 0.49	-1 0 1	2	
Random-effects DerSimonian-Laird model Sorted by: _meta_se		-	

Figure 13. Subgroup analysis for pain intensity (by pain type)

back pain Charlotte Gentili et al $0.20 [-0.22, 0.63]$ 6.24 Heterogeneity: $r^2 = 0.00, p = .$ $0.20 [-0.22, 0.63]$ 6.24 Cancer related pain $0.20 [-0.22, 0.63]$ 6.46 Sumit X. Raj et al $0.19 [-0.21, 0.59]$ 6.46 Heterogeneity: $r^2 = 0.51, l^2 = 92.23\%, H^2 = 12.87$ $0.34 [-0.51, 1.19]$ $0.34 [-0.51, 1.19]$ Rebecca L.H.Berman et al $0.02 [-0.47, 0.42]$ 6.13 Dowd, H et al $0.52 [-0.94, -0.09]$ 6.28 Wilson M et al $0.52 [-0.94, -0.09]$ 6.28 Emil Chiauzzi et al $0.15 [-0.25, 0.5]$ 6.33 Jiaxi Lin et al $0.15 [-0.25, 0.5]$ 6.33 Linda S.Ruehlmana et al $0.00 [-0.15, 0.33]$ 7.52 Heterogeneity: $r^2 = 0.00$ $0.38 [0.02, 0.75]$ 6.72 Bixi Lin et al $0.38 [0.02, 0.75]$ 6.33 Linda S.Ruehlmana et al $0.38 [0.02, 0.75]$ 6.72 Heterogeneity: $r^2 = 0.00, l^2 = .%, H^2 = .$ $0.38 [0.02, 0.75]$ 6.72 Test of $\theta_{i} = \theta_{i} Q(0) = 0.00, p = .$ $0.38 [0.02, 0.75]$ 6.72 Susanne Biódt et al $0.50 [0.23, 0.76]$ 7.38 Heter	Study of pain intensity		Effect Size with 95% CI	Weight (%)
Charlotte Gentili et al Heterogeneity: $r^{2} = 0.00$, $r^{2} = .%$, $H^{2} = .$ cancer related pain Yunheng Sun et al Karen Anderson et al Sunil X. Raj et al Heterogeneity: $r^{2} = 0.51$, $r^{2} = 92.23\%$, $H^{2} = 12.87$ Test of $\theta_{1} = \theta_{1}^{2} \cdot Q(2) = 25.75$, $p = 0.00$ chronic pain Rebecca L.H.Berman et al Dowd, H et al Wilson M et al Emil Chiauzzi et al Jiaxi Lin et al Linda S.Ruehlmana et al Heterogeneity: $r^{2} = 0.51$, $l^{2} = 92.44\%$, $H^{2} = 5.70$ Test of $\theta_{1} = \theta_{1}^{2} \cdot Q(5) = 28.48$, $p = 0.00$ fibromyalgia David A. Williams et al Heterogeneity: $r^{2} = 0.00$, $l^{2} = .\%$, $H^{2} = .$ Test of $\theta_{1} = \theta_{1}^{2} \cdot Q(0) = 0.00$, $p = .$ menstrual pain Susanne Blödt et al Heterogeneity: $r^{2} = 0.00$, $l^{2} = .\%$, $H^{2} = .$ Test of $\theta_{1} = \theta_{1}^{2} \cdot Q(0) = 0.00$, $p = .$ menstrual pain Susanne Blödt et al Heterogeneity: $r^{2} = 0.00$, $l^{2} = .\%$, $H^{2} = .$ Test of $\theta_{1} = \theta_{1}^{2} \cdot Q(0) = 0.00$, $p = .$ menstrual pain Susanne Blödt et al Heterogeneity: $r^{2} = 0.00$, $l^{2} = .\%$, $H^{2} = .$ Test of $\theta_{1} = \theta_{1}^{2} \cdot Q(0) = 0.00$, $p = .$ menstrual pain Susanne Blödt et al Heterogeneity: $r^{2} = 0.00$, $l^{2} = .\%$, $H^{2} = .$ Test of $\theta_{1} = \theta_{1}^{2} \cdot Q(0) = 0.00$, $p = .$ menstrual pain Susanne Blödt et al Heterogeneity: $r^{2} = 0.14$, $l^{2} = 85.19\%$, $H^{2} = 6.75$ Test of $\theta_{1} = \theta_{1}^{2} \cdot Q(2) = 13.51$, $p = 0.00$ Coverall Heterogeneity: $r^{2} = 0.14$, $l^{2} = 82.86\%$, $H^{2} = 5.83$ Test of $\theta_{1} = \theta_{1}^{2} \cdot Q(14) = 81.67$, $p = 0.00$ Test of goup differences: $Q_{0}(5) = 3.61$, $p = 0.61$ a b b b b c c c c c c c c	back pain			
Heterogeneity: $r^{2} = 0.00$, $l^{2} = .%$, $H^{2} = .$ cancer related pain Yunheng Sun et al Xaren Anderson et al Sumit X. Raj et al Heterogeneity: $r^{2} = 0.51$, $l^{2} = 92.23\%$, $H^{2} = 12.87$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(2) = 25.75$, $p = 0.00$ chronic pain Rebecca L.H.Berman et al Dowd, H et al Wilson M et al Emil Chiauzzi et al Jaki Lin et al David A. Williams et al Heterogeneity: $r^{2} = 0.13$, $l^{2} = 82.44\%$, $H^{2} = 5.70$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(2) = 25.75$, $p = 0.00$ chronic pain Rebecca L.H.Berman et al Dowd, H et al Linda S.Ruehlmana et al Heterogeneity: $r^{2} = 0.13$, $l^{2} = 82.44\%$, $H^{2} = 5.70$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(5) = 28.48$, $p = 0.00$ fibromyalgia David A. Williams et al Heterogeneity: $r^{2} = 0.00$, $l^{2} = .\%$, $H^{2} = .$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Biodt et al Heterogeneity: $r^{2} = 0.00$, $l^{2} = .\%$, $H^{2} = .$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(0) = 0.00$, $p = .$ osteoarthritis pain T. Cahner et al Christine Rini et al David A. $Q(2) = 13.51$, $p = 0.00$ Overall Heterogeneity: $r^{2} = 0.13$, $l^{2} = 85.19\%$, $H^{2} = 6.75$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(2) = 13.51$, $p = 0.00$ Coverall Heterogeneity: $r^{2} = 0.14$, $l^{2} = 82.48\%$, $H^{2} = 5.83$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(2) = 13.51$, $p = 0.00$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(14) = 81.67$, $p = 0.001$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(14) = 81.67$, $p = 0.001$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(14) = 81.67$, $p = 0.001$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(14) = 81.67$, $p = 0.001$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(14) = 81.67$, $p = 0.001$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(14) = 81.67$, $p = 0.001$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(14) = 81.67$, $p = 0.001$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(14) = 81.67$, $p = 0.001$ Test of $\theta_{2} = \theta_{1}^{2}$, $Q(14) = 81.67$, $p = 0.001$ Test of $\theta_{1} = \theta_{1}^{2}$, $Q(14) = 81.67$, $p = 0.001$ Test of $\theta_{2} = \theta_{1}^{2}$, $Q(14) = 8$	Charlotte Gentili et al		0.20 [-0.22, 0.63]	6.24
Test of $\theta_{i} = \theta_{j}^{-} Q(0) = -0.00, p = .$ cancer related pain Yunheng Sun et al Sumi X. Raje tal Heterogeneity: $r^{2} = 0.51, l^{2} = 92.23\%, H^{2} = 12.87$ Test of $\theta_{i} = \theta_{j}^{-} Q(2) = 25.75, p = 0.00$ chronic pain Rebecca L.H.Berman et al Dowd, H et al Wilson M et al Emil Chiauzzi et al Jiaki Lin et al Linda S.Ruehlmana et al Heterogeneity: $r^{2} = 0.13, l^{2} = 82.44\%, H^{2} = 5.70$ Test of $\theta_{i} = \theta_{j}^{-} Q(0) = 0.00, p^{2} menstrual pain Susame Biödt et al Heterogeneity: r^{2} = 0.00, l^{2} = .\%, H^{2} = .rest of \theta_{i} = \theta_{j}^{-} Q(0) = 0.00, p^{2} menstrual pain Susame Biödt et al Heterogeneity: r^{2} = 0.00, l^{2} = .\%, H^{2} = .rest of \theta_{i} = \theta_{j}^{-} Q(0) = 0.00, p^{2} menstrual pain Susame Biödt et al Heterogeneity: r^{2} = 0.00, l^{2} = .\%, H^{2} = .rest of \theta_{i} = \theta_{j}^{-} Q(0) = 0.00, p^{2} osteoarthritis pain T. Cahner et al Christine Rini et al Heterogeneity: r^{2} = 0.14, l^{2} = 82.86\%, H^{2} = 6.75Test of \theta_{i} = \theta_{j}^{-} Q(2) = 1.351, p = 0.00OverallHeterogeneity: r^{2} = 0.14, l^{2} = 82.86\%, H^{2} = 5.83Test of \theta_{i} = \theta_{j}^{-} Q(2) = 1.351, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(2) = 1.351, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(2) = 1.351, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(2) = 1.351, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q(4) = 81.67, p = 0.00Test of \theta_{i} = \theta_{j}^{-} Q$	Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$		0.20 [-0.22, 0.63]	
cancer related pain 1.34 [0.72, 1.96] 4.90 Xaren Anderson et al 0.19 [-0.21, 0.59] 6.46 Sunit X. Raj et al -0.38 [-0.66, -0.10] 7.29 Heterogeneity: $7^2 = 0.51$, $t^2 = 92.23\%$, $H^2 = 12.87$ -0.34 [-0.51, 1.19] 0.34 [-0.51, 1.19] Rebecca LI.H Berman et al -0.02 [-0.47, 0.42] 6.13 Dowd, H et al -0.52 [-0.94, -0.09] 6.28 Wilson M et al -0.52 [-0.94, -0.09] 6.28 Diad Lin et al -0.61 [-0.25, 0.57] 6.38 Linda S.Ruehimana et al -0.61 [-0.25, 0.57] 6.38 Heterogeneity: $r^2 = 0.13$, $t^2 = 82.44\%$, $H^2 = 5.70$ -0.38 [0.02, 0.75] 6.72 Test of $\theta_1 = \theta_2$; Q(5) = 28.48, $p = 0.00$ -0.38 [0.02, 0.75] 6.72 Bard A. Williams et al -0.38 [0.02, 0.75] 6.72 Heterogeneity: $r^2 = 0.00$, $t^2 = .%$, $H^2 = .$ -0.38 [0.02, 0.76] 7.38 Susanne Biödt et al -0.50 [0.23, 0.76] 7.38 Heterogeneity: $r^2 = 0.00$, $t^2 = .%$, $H^2 = .$ -0.50 [0.23, 0.76] 7.38 Costo [0.22, 0.44] -0.50 [0.23, 0.76] 7.38 Charling Rini et al -0.50 [0.23, 0.76] 7.38	Test of $\theta_i = \theta_j$: Q(0) = -0.00, p = .			
Yunhang Sun et al Karen Anderson et al Sumi X. Raj et al Heterogeneity: $\tau^2 = 0.51$, $t^2 = 92.23\%$, $H^2 = 12.87$ Test of $\theta_1 = \theta_1$: $Q(2) = 25.75$, $p = 0.00$ chronic pain Rebecca L.H.Berman et al Dowd, H et al Outilize at al Linda S.Ruehlmana et al Heterogeneity: $\tau^2 = 0.13$, $t^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_1 = \theta_1$: $Q(2) = 28.48$, $p = 0.00$ fibromyalgia David A. Williams et al Heterogeneity: $\tau^2 = 0.00$, $t^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$: $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Blödt et al Heterogeneity: $\tau^2 = 0.00$, $t^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$: $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Blödt et al Heterogeneity: $\tau^2 = 0.00$, $t^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$: $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Blödt et al Heterogeneity: $\tau^2 = 0.10$, $t^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$: $Q(0) = 0.00$, $p = .$ ostecoarthritis pain T. Calmer et al Christine Rini et al Chris	cancer related pain			
Karen Anderson et al Sunit X. Raj et al Heterogeneity: $r^2 = 0.51$, $l^2 = 92.23\%$, $H^2 = 12.87$ Test of $\theta_i = \theta_i$; $Q(2) = 25.75$, $p = 0.00$ chronic pain Rebecca L.H.Berman et al Dowd, H et al Wilson M et al Emil Chiauzzi et al Jiaak I.n et al Linda S.Ruehlmana et al Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_i = \theta_i$; $Q(0) = 20.0$, $p = .$ menstrual pain Susanne Blödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_i = \theta_i$; $Q(0) = 0.00$, $p = .$ osteoarthritis pain T. Calner et al Chaine et al Chaine Rin et al Chaine Rine Rin et al Chaine Rin et al C	Yunheng Sun et al		- 1.34 [0.72, 1.96]	4.90
Sunil X. Raj et al Heterogeneity: $r^2 = 0.51$, $l^2 = 92.23\%$, $H^2 = 12.87$ Test of $\theta_1 = \theta_1$: $Q(2) = 25.75$, $p = 0.00$ chronic pain Rebecca L.H.Berman et al Dowd, H et al Wilson M et al Emil Chiauzzi et al Linda S.Ruehimana et al Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_1 = \theta_1$: $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Biödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$: $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Biödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$: $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Biödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$: $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Biödt et al Heterogeneity: $r^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_1 = \theta_1$: $Q(2) = 13.51$, $p = 0.00$ Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_1 = \theta_1$: $Q(14) = 81.67$, $p = 0.00$ Test of $\theta_1 = \theta_1$: $Q(14) = 81.67$, $p = 0.00$ Test of $\theta_1 = \theta_1$: $Q(14) = 81.67$, $p = 0.00$ Test of $\theta_1 = \theta_1$: $Q(14) = 81.67$, $p = 0.00$ Test of group differences: $Q_n(5) = 3.61$, $p = 0.61$ Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_1 = \theta_1$: $Q(14) = 81.67$, $p = 0.00$	Karen Anderson et al		0.19 [-0.21, 0.59]	6.46
Heterogeneity: $r^2 = 0.51$, $l^2 = 92.23\%$, $H^2 = 12.87$ Test of $\theta_i = \theta_i$; $Q(2) = 25.75$, $p = 0.00$ chronic pain Rebecca L.H.Berman et al Dowd, H et al Wilson M et al Emil Chiauzzi et al Jiaxi Lin et al Linda S.Ruehimana et al Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_i = \theta_i$; $Q(5) = 28.48$, $p = 0.00$ fibromyalgia David A. Williams et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_i = \theta_i$; $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Biödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_i = \theta_i$; $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Biödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_i = \theta_i$; $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Biödt et al Heterogeneity: $r^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_i = \theta_i$; $Q(2) = 13.51$, $p = 0.00$ Overali Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_i$; $Q(2) = 13.51$, $p = 0.00$ Overali Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_i$; $Q(14) = 81.67$, $p = 0.00$ Test of group differences: $Q_b(5) = 3.61$, $p = 0.61$ Correl Functional pain Functional pain Functiona	Sunil X. Raj et al		-0.38 [-0.66, -0.10]	7.29
Test of $\theta_i = \theta_i$; $Q(2) = 25.75$, $p = 0.00$ chronic pain Rebecca L.H.Berman et al Dowd, H et al Dowd, H et al Discret Chauzzi et al Jiaxi Lin et al Linda S.Ruehlmana et al Heterogeneity: $\tau^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_i = \theta_i$; $Q(5) = 28.48$, $p = 0.00$ fibromyalgia David A. Williams et al Heterogeneity: $\tau^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_i = \theta_i$; $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Biödt et al Heterogeneity: $\tau^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_i = \theta_i$; $Q(0) = 0.00$, $p = .$ osteoarthritis pain T. Calner et al Christine Rini et al Heterogeneity: $\tau^2 = 0.19$, $l^2 = .85.19\%$, $H^2 = 6.75$ Test of $\theta_i = \theta_i$; $Q(2) = 13.51$, $p = 0.00$ Overall Heterogeneity: $\tau^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_i$; $Q(14) = 81.67$, $p = 0.00$ Test of $g_i = \theta_i$; $Q(14) = 81.67$, $p = 0.00$ Test of $g_i = \theta_i$; $Q(14) = 81.67$, $p = 0.00$ Test of $g_i = \theta_i$; $Q(14) = 81.67$, $p = 0.00$ Test of $g_i = \theta_i$; $Q(14) = 81.67$, $p = 0.00$ Test of $g_i = \theta_i$; $Q(14) = 81.67$, $p = 0.00$ Test of group differences: $Q_a(5) = 3.61$, $p = 0.61$	Heterogeneity: $\tau^2 = 0.51$, $I^2 = 92.23\%$, $H^2 = 12.87$		0.34 [-0.51, 1.19]	
chronic pain Rebecca L.H.Berman et al Dowd, H et al Wilson M et al Emit Chiauzzi et al Jiaxi Lin et al Linda S.Ruehlmana et al Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_1 = 0$; $Q(5) = 28.48$, $p = 0.00$ fibromyalgia David A. Williams et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_1 = 0$; $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Bidott et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$; $Q(0) = 0.00$, $p = .$ osteoarthritis pain T. Calner et al Christine Rin et al David A. U(2) = 13.51, $p = 0.00$ Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.00$ Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.00$ Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of group differences: $Q_4(5) = 3.61$, $p = 0.61$	Test of $\theta_i = \theta_j$: Q(2) = 25.75, p = 0.00			
Rebecca L.H.Berman et al $-0.02 [-0.47, 0.42]$ 6.13 Dowd, H et al $-0.52 [-0.94, -0.09]$ 6.28 Wilson M et al $-0.52 [-0.94, -0.09]$ 6.28 Emil Chiauzzi et al $-0.62 [-0.47, 0.42]$ 6.13 Jiaxi Lin et al $-0.52 [-0.94, -0.09]$ 6.28 Linda S.Ruehimana et al Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ $0.16 [-0.25, 0.57]$ 6.33 Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ $0.9 [-0.15, 0.33]$ 7.52 fibromyalgia $0.38 [0.02, 0.75]$ 6.72 David A. Williams et al $0.38 [0.02, 0.75]$ 6.72 Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ $0.38 [0.02, 0.75]$ 6.72 Test of $\theta_i = \theta_i$: $Q(0) = 0.00$, $p = .$ $0.50 [0.23, 0.76]$ 7.38 Meterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ $0.50 [0.23, 0.76]$ 7.38 Test of $\theta_i = \theta_i$: $Q(0) = 0.00$, $p = .$ $0.08 [-0.34, 0.50]$ 6.33 Otherali $0.08 [-0.34, 0.50]$ 6.33 Chief I al $0.50 [0.23, 0.76]$ 7.38 Heterogeneity: $\tau^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ $0.86 [0.55, 1.16]$ 7.13 Otherali <t< td=""><td>chronic pain</td><td></td><td></td><td></td></t<>	chronic pain			
Dowd, H et al Wilson M et al Emil Chiauzzi et al Jiaxi Lin et al Linda S.Ruehlmana et al Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_1 = \theta_1$: Q(5) = 28.48, p = 0.00 fibromyalgia David A. Williams et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$: Q(0) = 0.00, p = . menstrual pain Susanne Blödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$: Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al David A. Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al David Bossen et al Heterogeneity: $r^2 = 0.14$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_1 = \theta_1$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_1 = \theta_1$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	Rebecca L.H.Berman et al		-0.02 [-0.47, 0.42]	6.13
Wilson M et al Emil Chiauzzi et al Jiaxi Lin et al Linda S.Ruehlmana et al Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_l = \theta_l^2$: Q(5) = 28.48, p = 0.00 fibromyalgia David A. Williams et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_l = \theta_l^2$: Q(0) = 0.00, p = . menstrual pain Susanne Biödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_l = \theta_l^2$: Q(0) = 0.00, p = . stecarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $r^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_l = \theta_l^2$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_l = \theta_l^2$: Q(14) = 81.67, p = 0.00 Test of group differences: Q ₀ (5) = 3.61, p = 0.61 o	Dowd, H et al		-0.52 [-0.94, -0.09]	6.28
Emil Chiauzzi et al Jiaxi Lin et al Linda S.Ruehlmana et al Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_l = \theta_l$: Q(5) = 28.48, p = 0.00 fibromyalgia David A. Williams et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_l = \theta_l$: Q(0) = 0.00, p = . menstrual pain Susanne Blödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_l = \theta_l$: Q(0) = 0.00, p = . menstrual pain Susanne Blödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_l = \theta_l$: Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $r^2 = 0.14$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_l = \theta_l$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_l = \theta_l$: Q(14) = 81.67, p = 0.01 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	Wilson M et al		0.16 [-0.25, 0.57]	6.38
Jiaxi Lin et al Linda S.Ruehlmana et al Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_1 = \theta_1$; $Q(5) = 28.48$, $p = 0.00$ fibromyalgia David A. Williams et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$; $Q(0) = 0.00$, $p = .$ menstrual pain Susanne Blödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_1 = \theta_1$; $Q(0) = 0.00$, $p = .$ osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $r^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_1 = \theta_1$; $Q(2) = 13.51$, $p = 0.00$ Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.01$ Test of $g_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.01$ Test of $g_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.01$ Test of $g_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.01$ Test of $g_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.01$ Test of $g_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.01$ Test of $g_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.01$ Test of $g_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.01$ Test of $g_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.01$ Test of $g_1 = \theta_1$; $Q(14) = 81.67$, $p = 0.01$ Test of group differences: $Q_h(5) = 3.61$, $p = 0.61$	Emil Chiauzzi et al		0.76 [0.48, 1.05]	7.27
Linda S.Ruehlmana et al Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_i = \theta_i$: Q(5) = 28.48, p = 0.00 fibromyalgia David A. Williams et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_i = \theta_i$: Q(0) = 0.00, p = . menstrual pain Susanne Biödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_i = \theta_i$: Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $r^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_i = \theta_i$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_i$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	Jiaxi Lin et al		0.13 [-0.14, 0.41]	7.30
Heterogeneity: $r^2 = 0.13$, $l^2 = 82.44\%$, $H^2 = 5.70$ Test of $\theta_i = \theta_i$: Q(5) = 28.48, p = 0.00 fibromyalgia David A. Williams et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_i = \theta_i$: Q(0) = 0.00, p = . menstrual pain Susanne Blödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .\%$, $H^2 = .$ Test of $\theta_i = \theta_i$: Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $r^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_i = \theta_i$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_i$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61	Linda S.Ruehlmana et al		0.09 [-0.15, 0.33]	7.52
Test of $\theta_{i} = \theta_{i}$: Q(5) = 28.48, p = 0.00 fibromyalgia David A. Williams et al Heterogeneity: $r^{2} = 0.00$, $l^{2} = .%$, $H^{2} = .$ Test of $\theta_{i} = \theta_{i}$: Q(0) = 0.00, p = . menstrual pain Susanne Blödt et al Heterogeneity: $r^{2} = 0.00$, $l^{2} = .%$, $H^{2} = .$ Test of $\theta_{i} = \theta_{i}$: Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $r^{2} = 0.19$, $l^{2} = 85.19\%$, $H^{2} = 6.75$ Test of $\theta_{i} = \theta_{i}$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^{2} = 0.14$, $l^{2} = 82.86\%$, $H^{2} = 5.83$ Test of $\theta_{i} = \theta_{i}$: Q(14) = 81.67, p = 0.00 Test of group differences: Q ₄ (5) = 3.61, p = 0.61 -1 0 1 2	Heterogeneity: $\tau^2 = 0.13$, $I^2 = 82.44\%$, $H^2 = 5.70$		0.12 [-0.20, 0.44]	
fibromyalgia David A. Williams et al $0.38 [0.02, 0.75]$ 6.72 Heterogeneity: $r^2 = 0.00, l^2 = .%, H^2 = .$ $0.38 [0.02, 0.75]$ 6.72 Test of $\theta_i = \theta_i$: Q(0) = 0.00, p = . $0.38 [0.02, 0.75]$ 6.72 menstrual pain $0.38 [0.02, 0.75]$ 6.72 Susanne Blödt et al $0.50 [0.23, 0.76]$ 7.38 Heterogeneity: $r^2 = 0.00, l^2 = .%, H^2 = .$ $0.50 [0.23, 0.76]$ 7.38 Test of $\theta_i = \theta_i$: Q(0) = 0.00, p = . $0.50 [0.23, 0.76]$ 7.38 Osteoarthritis pain $0.50 [0.23, 0.76]$ 6.33 Christine Rini et al $0.08 [-0.34, 0.50]$ 6.33 Daniël Bossen et al $0.86 [0.55, 1.16]$ 7.13 Heterogeneity: $r^2 = 0.19, l^2 = 85.19\%, H^2 = 6.75$ $0.86 [0.55, 1.16]$ 7.13 Test of $\theta_i = \theta_i$: Q(2) = 13.51, p = 0.00 \bullet $0.25 [0.03, 0.46]$ Heterogeneity: $\tau^2 = 0.14, l^2 = 82.86\%, H^2 = 5.83$ \bullet $0.25 [0.03, 0.46]$ Heterogeneity: $\tau^2 = 0.14, l^2 = 82.86\%, H^2 = 5.83$ \bullet $0.25 [0.03, 0.46]$ Test of $group$ differences: $Q_b(5) = 3.61, p = 0.61$ -1 0 1	Test of $\theta_i = \theta_j$: Q(5) = 28.48, p = 0.00		-00110799900 • 00090000000000000000000000	
David A. Williams et al Heterogeneity: $r^2 = 0.00$, $l^2 = .%$, $H^2 = .$ Test of $\theta_1 = \theta_1$; Q(0) = 0.00, p = . menstrual pain Susanne Blödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .%$, $H^2 = .$ Test of $\theta_1 = \theta_1$; Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $r^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_1 = \theta_1$; Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_1 = \theta_1$; Q(14) = 81.67, p = 0.00 Test of group differences: $Q_b(5) = 3.61$, p = 0.61 -1 0 0 1 2 0.38 [0.02, 0.75] 0.38 [0.02, 0.75] 0.50 [0.23, 0.76] 0.50 [0.23, 0.76] 0.25 [0.03, 0.46]	fibromyalgia			
Heterogeneity: $r^{2} = 0.00, t^{2} = .%, t^{2} = .$ Test of $\theta_{i} = \theta_{j}$: Q(0) = 0.00, p = . menstrual pain Susanne Blödt et al Heterogeneity: $r^{2} = 0.00, t^{2} = .%, t^{2} = .$ Test of $\theta_{i} = \theta_{j}$: Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $r^{2} = 0.19, t^{2} = 85.19\%, t^{2} = 6.75$ Test of $\theta_{i} = \theta_{j}$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^{2} = 0.14, t^{2} = 82.86\%, t^{2} = 5.83$ Test of $\theta_{i} = \theta_{j}$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 u	David A. Williams et al		0.38 [0.02, 0.75]	6.72
Test of $\theta_{1} = \theta_{1}$: Q(0) = 0.00, p = . menstrual pain Susanne Blödt et al Heterogeneity: $r^{2} = 0.00, 1^{2} = .\%, H^{2} = .$ Test of $\theta_{1} = \theta_{1}$: Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $r^{2} = 0.19, 1^{2} = 85.19\%, H^{2} = 6.75$ Test of $\theta_{1} = \theta_{1}$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^{2} = 0.14, 1^{2} = 82.86\%, H^{2} = 5.83$ Test of $\theta_{1} = \theta_{1}$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	Heterogeneity: $r^2 = 0.00$, $I^2 = .\%$, $H^2 = .$	-	0.38 [0.02, 0.75]	
menstrual pain Susanne Blödt et al $0.50 [0.23, 0.76]$ 7.38 Heterogeneity: $r^2 = 0.00, l^2 = .%, H^2 = .$ $0.50 [0.23, 0.76]$ 7.38 Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = . $0.50 [0.23, 0.76]$ 7.38 osteoarthritis pain $0.50 [0.23, 0.76]$ 7.38 T. Calner et al $0.08 [-0.34, 0.50]$ 6.33 Christine Rini et al $0.36 [0.55, 1.16]$ 7.13 Daniël Bossen et al $0.36 [0.55, 1.16]$ 7.13 Heterogeneity: $r^2 = 0.19, l^2 = 85.19\%, H^2 = 6.75$ $0.36 [-0.18, 0.90]$ $0.36 [-0.18, 0.90]$ Overall $0.25 [0.03, 0.46]$ $0.25 [0.03, 0.46]$ Heterogeneity: $r^2 = 0.14, l^2 = 82.86\%, H^2 = 5.83$ $0.25 [0.03, 0.46]$ $0.25 [0.03, 0.46]$ Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00 $0.25 [0.03, 0.46]$ $0.25 [0.03, 0.46]$	Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = .			
Susanne Blödt et al Heterogeneity: $r^2 = 0.00$, $l^2 = .%$, $H^2 = .$ Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $r^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_i = \theta_j$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2 $0.50 [0.23, 0.76]$ $7.380.50 [0.23, 0.76]$ $0.50 [0.23, 0.76]$ $0.50 [0.23, 0.76]$ $0.50 [0.23, 0.76]$ $0.50 [0.23, 0.76]$ $0.50 [0.23, 0.76]$ $0.08 [-0.34, 0.50]$ $6.330.10 [-0.27, 0.47]$ $6.670.36 [-0.18, 0.90]$ $0.25 [0.03, 0.46]$	menstrual pain			
Heterogeneity: $r^2 = 0.00, l^2 = .\%, H^2 = .$ Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $r^2 = 0.19, l^2 = 85.19\%, H^2 = 6.75$ Test of $\theta_i = \theta_j$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^2 = 0.14, l^2 = 82.86\%, H^2 = 5.83$ Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	Susanne Blödt et al		0.50 [0.23, 0.76]	7.38
Test of $\theta_i = \theta_i$: Q(0) = 0.00, p = . osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $\tau^2 = 0.19$, $I^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_i = \theta_i$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $\tau^2 = 0.14$, $I^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_i$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$	-	0.50 [0.23, 0.76]	
osteoarthritis pain T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $\tau^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_i = \theta_j$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $\tau^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00 Test of group differences: $Q_b(5) = 3.61$, p = 0.61	Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = .	•	Standard (1997)	
T. Calner et al Christine Rini et al Daniël Bossen et al Heterogeneity: $\tau^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_i = \theta_i$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $\tau^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_i$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	osteoarthritis pain			
Christine Rini et al Daniël Bossen et al Heterogeneity: $\tau^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_i = \theta_j$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $\tau^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	T. Calner et al		0.08 [-0.34, 0.50]	6.33
Daniël Bossen et al Heterogeneity: $\tau^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_i = \theta_j$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $\tau^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	Christine Rini et al		0.10 [-0.27, 0.47]	6.67
Heterogeneity: $r^2 = 0.19$, $l^2 = 85.19\%$, $H^2 = 6.75$ Test of $\theta_i = \theta_j$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $r^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	Daniël Bossen et al		0.86 [0.55, 1.16]	7.13
Test of $\theta_i = \theta_i$: Q(2) = 13.51, p = 0.00 Overall Heterogeneity: $\tau^2 = 0.14$, $I^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_i$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	Heterogeneity: $\tau^2 = 0.19$, $I^2 = 85.19\%$, $H^2 = 6.75$		0.36 [-0.18, 0.90]	
Overall $0.25 [0.03, 0.46]$ Heterogeneity: $\tau^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00 Test of group differences: $Q_b(5) = 3.61$, p = 0.61 -1 0	Test of $\theta_i = \theta_j$: Q(2) = 13.51, p = 0.00			
Heterogeneity: $\tau^2 = 0.14$, $l^2 = 82.86\%$, $H^2 = 5.83$ Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61	Overall		0.25[0.03 0.46]	
Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00 Test of group differences: Q _b (5) = 3.61, p = 0.61 -1 0 1 2	Heterogeneity: $r^2 = 0.14$. $l^2 = 82.86\%$. $H^2 = 5.83$	•		
Test of group differences: $Q_b(5) = 3.61$, p = 0.61	Test of $\theta_1 = \theta_1$; Q(14) = 81.67, p = 0.00			
Test of group differences: $Q_b(5) = 3.61$, p = 0.61 -1 0 1 2				
-1 0 1 2	Test of group differences: $Q_b(5) = 3.61$, p = 0.61	-1 0 1	2	
Random-effects DerSimonian-Laird model	Random-effects DerSimonian-Laird model	-, , , , ,	-	

Figure 14a Subgroup analysis for pain intensity (by country)

tudy of pain intensity		Effect Size with 95% CI	Weight (%)
China			
Yunheng Sun et al		1.34 [0.72, 1.96]	4.90
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$		1.34 [0.72, 1.96]	
Test of $\theta_i=\theta_j;$ Q(0) = -0.00, p = .			
Germany			
Charlotte Gentili et al		0.20 [-0.22, 0.63]	6.24
Jiaxi Lin et al		0.13 [-0.14, 0.41]	7.30
Susanne Blödt et al		0.50 [0.23, 0.76]	7.38
Heterogeneity: τ^2 = 0.02, I^2 = 45.91%, H^2 = 1.85	•	0.29 [0.05, 0.54]	
Test of $\theta_i = \theta_j$: Q(2) = 3.70, p = 0.16			
Ireland			
Dowd, H et al		-0.52 [-0.94, -0.09]	6.28
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$	-	-0.52 [-0.94, -0.09]	
Test of $\theta_i = \theta_j$: Q(0) = 0.00, p = .			
Netherlands			
Daniël Bossen et al		0.86 [0.55, 1.16]	7.13
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$		0.86 [0.55, 1.16]	
Test of $\theta_i=\theta_j;$ Q(0) = 0.00, p = .			
Norway			
Sunil X. Raj et al		-0.38 [-0.66, -0.10]	7.29
Heterogeneity: $\tau^2 = 0.00$, $I^2 = .\%$, $H^2 = .$	•	-0.38 [-0.66, -0.10]	
Test of $\theta_i=\theta_j;$ Q(0) = -0.00, p = .			
USA			
Rebecca L.H.Berman et al		-0.02 [-0.47, 0.42]	6.13
T. Calner et al		0.08 [-0.34, 0.50]	6.33
Wilson M et al		0.16 [-0.25, 0.57]	6.38
Karen Anderson et al		0.19[-0.21, 0.59]	6.46
Christine Rini et al		0.10 [-0.27, 0.47]	6.67
David A. Williams et al		0.38 [0.02, 0.75]	6.72
Emil Chiauzzi et al		0.76 [0.48, 1.05]	7.27
Linda S.Ruehlmana et al		0.09 [-0.15, 0.33]	7.52
Heterogeneity: $\tau^2 = 0.05$, $I^2 = 61.54\%$, $H^2 = 2.60$	•	0.23 [0.03, 0.44]	
Test of $\theta_i = \theta_j$: Q(7) = 18.20, p = 0.01			
Overall	•	0.25 [0.03, 0.46]	
Heterogeneity: r^2 = 0.14, I^2 = 82.86%, H^2 = 5.83			
Test of $\theta_i = \theta_j$: Q(14) = 81.67, p = 0.00			
Test of group differences: $Q_b(5) = 59.19$, p = 0.00	· · · · · · · · · · · · · · · · · · ·		
	-1 0 1 2	2	
Random-effects DerSimonian-Laird model Sorted by: _meta_se			



Figure 14b Geographical spread of data collected for the systematic review

Figure 15. Sensitivity analysis without 3 BAME studies^{33,41,60}

Study of pain intensity	Percent of white						Effect Siz with 95%	ze Cl	Weight (%)
Rebecca L.H.Berman et al	50%			-			-0.02 [-0.47,	0.42]	7.35
Charlotte Gentili et al	Not provided		9	-	<u> </u>		0.20 [-0.22,	0.63]	7.52
Dowd, H et al	94.4%were British	-	_	_			-0.52 [-0.94,	-0.09]	7.57
T. Calner et al	Not provided		-	-			0.08 [-0.34,	0.50]	7.64
Wilson M et al	Not provided		-				0.16 [-0.25,	0.57]	7.73
Christine Rini et al	70%		-	-	_		0.10 [-0.27,	0.47]	8.15
David A. Williams et al	97.46%						0.38 [0.02,	0.75]	8.23
Daniël Bossen et al	Not provided				_		0.86 [0.55,	1.16]	8.86
Sunil X. Raj et al	Not provided		_	_			-0.38 [-0.66,	-0.10]	9.11
Jiaxi Lin et al	Not provided				_		0.13 [-0.14,	0.41]	9.12
Susanne Blödt et al	Not provided				_	-	0.50 [0.23,	0.76]	9.24
Linda S.Ruehlmana et al	82%				_		0.09 [-0.15,	0.33]	9.47
Overall				-			0.14 [-0.07,	0.351	
Heterogeneity: $r^2 = 0.11$, $l^2 = 79.49\%$, $H^2 = 4.88$									
Test of $\theta_1 = \theta_1$: Q(11) = 53.63, p = 0.00									
Test of $\theta = 0$: $z = 1.29$, $p = 0.20$									
		-1	5	ó	.5	1			
Random-effects DerSimonian-Laird model Sorted by: _meta_se									

Number of stud	ies = 4				Root MSE	= 1.207
Std_Eff	Coef.	Std. Err.	t	P> t	[95% Conf.	Interval]
slope bias	.5244641 -2.348156	.3811539 2.390633	1.38 -0.98	0.303 0.430	-1.115509 -12.63422	2.164437 7.937908

Figure 16. Sensitivity analysis without 3 BAME studies^{33,41,60}

Test of H0: no small-study effects

P = 0.430

(sub-grouped by digital applications)

Study of pain intensity		Effect Size with 95% Cl		
		with 95% CI	(%)	
Chatbots	-	0.001.0.17.0.101	7.05	
Rebecca L.H.Berman et al		-0.02 [-0.47, 0.42]	7.35	
Heterogeneity: $t^{-} = 0.00$, $t^{-} = .\%$, $H^{-} = .$		-0.02[-0.47, 0.42]		
l est of $\theta_i = \theta_j$: Q(0) = 0.00, p = .				
mobile apps				
Charlotte Gentili et al		0.20 [-0.22, 0.63]	7.52	
Dowd, H et al		-0.52 [-0.94, -0.09]	7.57	
T. Calner et al		0.08 [-0.34, 0.50]	7.64	
Jiaxi Lin et al		0.13 [-0.14, 0.41]	9.12	
Susanne Blödt et al		0.50 [0.23, 0.76]	9.24	
Linda S.Ruehlmana et al		0.09 [-0.15, 0.33]	9.47	
Heterogeneity: τ^2 = 0.06, I^2 = 69.78%, H^2 = 3.31	-	0.10 [-0.14, 0.35]		
Test of $\theta_i = \theta_j$: Q(5) = 16.54, p = 0.01				
web-application				
Wilson M et al		0.16 [-0.25, 0.57]	7.73	
Christine Rini et al		0.10 [-0.27, 0.47]	8.15	
David A. Williams et al		0.38 [0.02, 0.75]	8.23	
Daniël Bossen et al		- 0.86 [0.55, 1.16]	8.86	
Sunil X. Raj et al		-0.38 [-0.66, -0.10]	9.11	
Heterogeneity: τ^2 = 0.24, I^2 = 88.92%, H^2 = 9.02		0.22 [-0.23, 0.68]		
Test of $\theta_i = \theta_j$: Q(4) = 36.10, p = 0.00				
Overall	•	0.14 [-0.07, 0.35]		
Heterogeneity: r ² = 0.11, I ² = 79.49%, H ² = 4.88				
Test of $\theta_i = \theta_j$: Q(11) = 53.63, p = 0.00				
Test of group differences: $Q_{\rm b}(2)$ = 0.58, p = 0.75		- ::		
	-15 0 .5 1			
Random-effects DerSimonian-Laird model Sorted by: _meta_se				



Figure 17. (a) funnel plot for pain intensity; (b) egger's test for pain intensity.



Figure 18. (a) funnel plot for depression; (b) egger's test for depression.



Figure 19. (a) funnel plot for anxiety; (b) egger's test for anxiety.





Number of stud	dies = 4				Root MSE	=	1.207
Std_Eff	Coef.	Std. Err.	t	P> t	[95% Conf.	Inte	erval]
slope	.5244641	.3811539	1.38	0.303	-1.115509	2.3	164437
bias	-2.348156	2.390633	-0.98	0.430	-12.63422	7.9	937908

Test of H0: no small-study effects P = 0.430





